The palmprint recognition systems.
\r\n\tThe primary objective of this book is to provide the specialists involved in the clinical management and experimental research of acute and chronic leukemias updates on the theoretical aspects as well as state-of-the-art diagnostic and clinical management of acute and chronic leukemias.
\r\n\r\n\tThe book is intended to cover a broad spectrum of leukemia-related topics such as:
\r\n\t-novel and still evolving insights into the biology and diagnosis and how these result in new drug approvals and new therapeutic options with a focus on molecular and immunotherapeutic targeted therapeutics,
\r\n\t- the molecular and functional features of leukemic stem cells and their interaction with the microenvironment,
\r\n\t- preleukemic hematopoiesis and clonal diversity,
\r\n\t- new standard treatment algorithms,
\r\n\t- mechanisms of resistance and disease progression
\r\n\t- diagnosis and management of rare acute leukemia subtypes,
\r\n\t- Covid-19 aspects in specific leukemia categories,
\r\n\t- real-world data
\r\n\t- new drugs in development
Advances in Artificial Intelligence methods have skyrocketed in the past decade, especially in the medical space where the impact of healthcare reaches individuals across a broad spectrum of communities. In particular, machine learning (ML) researchers have gained access to a large quantity of high quality medical data, aggregated by health providers as a result of implementing hospital management systems. A crucial element of these management systems is electronic medical records (EMRs), which are rich in valuable real world data on patient, clinical and genomic data. An EMR is a digitized record of a medical occurrence documented either during or after an encounter by a medical professional in a medical environment. For example, the results of a blood test administered at a hospital may be part of an EMR. Clinical notes taken by the doctor in a routine check-up at a local clinic are also included in the EMR. EMRs can come in the form of structured data such as drug orders, medications, laboratory tests and diagnosis codes or unstructured data such as text-based clinical progress notes, radiology reports and pathology findings [1].
When EMRs are amalgamated to create a longitudinal overview of a specific patient, this larger unit of digitized records is called an electronic health record (EHR). Since EHRs contain historical data, they are used to track the health progression of patients over time. Although in some sources, the terms EMR and EHR are used interchangeably, or are sometimes referred to as the electronic patient record, for simplicity the above definitions are used here. Another digital record is the personal health record, which is the electronic medical data that the individual may choose to provide to the medical institutions or health providers, however issues of personal choice in volunteering data are beyond the scope of this chapter, so we do not consider the personal health record here.
Today, providers produce EMRs with the hope to provide a centralized source of medical data, which helps increase care coordination. With a standardized EMR system, if an individual decides to switch health providers, the medical data can seamlessly transfer to the new institutions. Furthermore, centralized medical data reduces duplication of records and identifies missing patient data, which reduces valuable time spent in clinical care. Compared to the traditional paperwork, EMRs significantly decreases disease identification time, making healthcare more time efficient and cost effective [2, 3]. In this sense, the EMRs improve quality of care.
In reality, there are issues in introducing EMRs into healthcare provider systems such as implementation and workflow disruptions. Implementation requires funding, necessary staff, and up to date digital technology. Institutions and geographic regions with ample resources will benefit from this implementation. However, for many smaller scale practices, implementation is not financially viable. For regions where institutions do not have access to technology that enables the production, storage and sharing of EMRs, this concept does not make sense. Furthermore, workflow is disrupted when clinicians and other medical professionals must alter their workflow in order to complete these documents. EMRs are notoriously unpopular in the medical community as it burdens professionals to constantly type on their computer instead of caring for their patients. Burdened professionals do not see the long term benefits and the reality in medical environments is that EMRs are primarily used for financial and administrative purposes. For example, although there are no global standards to what may be included in an EHR, it must always have billing codes, which are used for administrative purposes such as reimbursement or auditing reasons.
Despite these institutional challenges, EMRs are gaining traction in the biomedical space because there is potential to extract important biomedical conclusions from EMRs. As of December 2019, there are just under 2.1 million papers published on electronic medical records in drug development and research within google scholar [4]. Because EMRs are untapped and vast in quantity, researchers are particularly focused on testing ML methods on EMRs. EMRs also provide resources to carry out clinical trials at a lower cost and with reduced duration in terms of efficiency gained from automation and having better data sources. With a manual approach to identify and extract high value data, drug research on EMRs are not scalable and are extremely costly to employ domain experts for data extraction. The push for medical document digitization in conjunction with recent development in ML methods, such as natural language processing (NLP) that allows for machines to mimic human comprehension of written text, has allowed the outsourcing of these research tasks to machines and further facilitate drug research.
In the context of ML methods, EMRs pose problems such as how EMRs do not have a standardized formatting, how minorities could be underrepresented, and how EMRs contain human errors. Today in the healthcare space, EMRs exist in abundance but were not originally created with a large scale data-mining vision [5]. Rather, providers replaced paper-work with electronic records to keep up with the technological pace of the 21st century. Such digitization of the traditional paperwork was done on an ad-hoc basis and many healthcare institutions independently regulate EMRs to create a highly heterogeneous data set [6, 7]. This heterogeneity makes data pre-processing for ML methods time consuming and financially costly if domain experts are required for this task. Another difficulty stems from the issue of institutions and geographic regions not having access to technology or financial resources to implement EMRs. The lack of EMRs in particular communities means those individuals are not electronically visible. In this sense, EMRs will not be able to sample certain populations in the world. These underrepresented populations will not have as much benefit from the biomedical success of EMRs as those represented in the sample populations, increasing the inequality of medical care. Lastly, basic human error in the EMRs will affect analysis performed on these data sets, if they are not corrected. In addition, the EMRs come from different institutions, which may enter their data differently. Without a standardized requirement for EMRs, some parts will be missing core information and the operation is not scalable.
This introduction started with a brief discussion of what an EMR is and how we define it in the absence of international unifying standards. This chapter will now move on to an overview of how machine learning techniques, applied to EMRs, are influencing three key areas of biomedical research and drug discovery: (1) phenotype-genotype associations, (2) clinical trials, and (3) pharmacovigilance.
Firstly, we assess the impact of EMRs on making accurate phenotype-genotype associations, where physical traits are linked to specific locus in the genome. We then look at EMRs in the context of clinical drug trials and pharmacovigilance, which together amount to the tracking of a drug’s efficacy and adverse side-effects both before and after it is licensed and used. Finally, a number of different case studies are looked at in detail, and we present a vision of how integrated EMRs and ML-driven EMR drug research could be implemented in the future.
Phenotype-genotype association is the correspondence between a person’s genetic makeup—their genotype, and the observable characteristics or pathologies that are a product of their genetics interacting with the environment—their phenotype. In the medical space, researchers study phenotype-genotype associations because variations in the human genome affect how a person exhibits phenotypic traits, so to understand phenotype-genotype relations is to have biological insight into disease mechanisms. Furthermore, phenotype-genotype associations are important in drug discovery because phenotype targets are used to identify viable drug targets within the human genome and are needed to understand the chemistry of a potential drug within the human biology. Understanding phenotype-genotype associations has useful downstream applications in many fields including disease categorization, phenotype discovery, pharmacogenomics, drug–drug interaction (DDI), and adverse drug event (ADE) detection, and genome-wide and phenome-wide association studies [8].
Phenotype-genotype association research owes its foundation to the genome-wide association studies (GWAS) studies that were driven by the potential of genetic variations modulating disease risks, expression and progression. Although the GWAS studies accumulated vast amount of genetic data, a remaining challenge is translating genetic markers to its associated phenotype [9, 10]. A high-throughput solution to such challenge is to harness phenotype data embedded in EMRs.
In a medical provider setting, clinical professionals observe phenotypes on a daily basis to diagnose diseases because phenotypic traits are manifestations of an individual’s genome interacting with the environment. Such diagnosis is recorded extensively in EMRs, making them rich in phenotype-related data. Following the human genome project and the following development in sequencing whole genomes, EMRs can now feasibly link an individual’s genome as part of their medical data.
However, linking genomic data to EHRs is not common in clinical practice. This is due to the combination of clinics offloading new sequencing technology to bioinformatics laboratories and the lack of infrastructure for integrating the processed genomic data into EHRs [11]. Unlike most clinical laboratory tests, genomic testing requires data curation during the bioinformatics pipelines. Therefore, when laboratories send genomic tests back to the original provider, the format or structure of that data may not be directly compatible with the local EHR system [12]. In 2016, laboratories were still physically mailing or faxing genomic reports in PDFs, which is a format that is extremely difficult for machines to read and interpret [12]. This clinical hurdle aside, in biomedical research this genomic inclusion in EHRs shows potential in secondary use as raw data from which to draw medically meaningful results [2, 12, 13]. Assuming that the EMR has adequate phenomic and genomic data on an individual, algorithms can translate raw data in EMRs to phenotype data, which in turn can be associated with the genomic data.
This section will focus on studies that cover phenotype-genotype research using EMRs that aims to advance drug research, with particular attention to the machine learning methods used in these cases. In a broad sense, this phenotype-genotype application of EMRs to drug research has two major tasks. First is to identify phenotypes contained in EMRs and second is to extract the phenotype to genotype associations.
One of the validated processes to identify phenotypic traits from EMRs is the use of standardized codes. Standardized codes have been designed for specific medical needs and are heavily used in the structured documentation in EMRs. When composing EMR’s, medical professionals use an internationally standardized set of codes for reporting disease and health conditions called the International Classification of Disease (ICD) developed by the World Health Organization (WHO). For example, the ICD code may be a procedure code that indicates what medical procedures a patient has received during hospitalization or a disease code that specifies a clinician’s diagnosis. Although standardized, the recorded ICD relies on a consistent interpretation of the ICD criteria for accuracy and relevancy, which will inevitably vary between clinicians, departments and institutions. However, researchers circumvent the larger issue of heterogenous EMR data types, which might range from character strings in clinical notes to matrices of pixels in radiology images, by focusing on these codes that are a standardized part of EHRs.
In the context of AI, using standardized codes is advantageous because they vastly reduce the set of possible inputs to any given machine learning algorithm. In practical terms, the data requires little pre-processing, since the codes already contain accurate and rich medical information described by domain experts. Computation becomes scalable as less pre-processing means less manual work involved, which is a necessity when extracting phenotypic data. Inevitably, there are a multitude of competing standards. As mentioned earlier, the ICD is consistently updated in order to internationally keep track of morbidity and mortality statistics with its eleventh version being adopted and replacing previous revisions starting 1 January 2022 [14]. In addition to the ICD, the US government has designed the ICD Clinical Modification (ICD-CM), which is based upon ICD but tailored to the US healthcare market. The Clinical Classification Software for ICD-CM, developed by the US Agency for Healthcare Research and Quality, is a further development to the ICD-CM that regroups codes into clinically relevant categories. New standards do not have to be based upon existing ones, however. Phecodes is a standard specifically designed for biomedical research and to facilitate phenome-wide association studies, first published in 2010 [15, 16]. In 2017, these different sets of standardized EMR codes (ICD, ICD-CM, phecodes) were compared based on their ability to create correctly pair single nucleotide polymorphism (SNP), which is a nucleotide level genetic variation, to the corresponding phenotype, and it was found that the phecodes performed markedly better than the ICD based standards [15, 17]. It is perhaps not surprising that the phecodes performed best. Phecodes were developed for research purposes, whereas ICD and related standards are more focused on record keeping and streamlining the financial aspect of healthcare. These results illustrate how common EMR codes used in hospitals are not well designed for ML purposes. Although these codes are a convenient aspect within the context of diverse data from EMRs, care must be taken when designing algorithms, which repurpose the codes for phenotype extraction.
EMRs often contain a mixture of standardized codes and free-text. To improve upon methods that only consider codes, machine learning tools, largely based upon NLPs, have been developed to collect more phenotypic data from data sources beyond standardized codes such as textual clinical notes, textual discharge summaries and radiology reports [1, 18, 19, 20, 21]. Liao et al. developed a multimodal automated phenotyping (MAP) algorithm to leverage both ICD codes and EMR textual narratives based on the Unified Medical Language System [18]. MAP is multimodal because it can extract entities such as ICDs, medical NLP concepts and healthcare utilization information related to a certain phenotype from both codes and free text. Using MAP, Liao et al. analyzed those entities by different latent mixture models to predict whether a patient had a certain phenotypic feature. Liao et al. ran the algorithm through a validation dataset that contained labelled data with one of 16 unique phenotypes to show that MAP can extract relevant and phenotype-specific entities at comparable accuracy to those identified by a manual approach (AUC-MAP = 0.943, AUC-manual = 0.941). Another example of successful high throughput method to extract phenotypes from EMRs is PheNorm, which harnesses standardized codes as training labels and does not require domain experts to label the training set, making the model highly scalable and cost effective for phenotype research [19]. In the face of the ML hype, it is naive to say that ML methods are superior and domain experts will become superfluous in the future. For example, Coquet et al. demonstrated the use of NLP methods and a Convolutional Neural Network (CNN) method to create word embeddings in clinical notes to automate clinical phenotyping of prostate cancer patients [20]. In this particular case, the phenotyping accuracy of CNN model (F-measure = 0.918) surpassed that of the rule-based model (F-measure = 0.897) [20] and the authors concluded that the mixture of both models can lead to even better precision and accuracy. These statistics in which the CNN model, which is a class of deep neural networks, outperformed the rule-based model, an example of human driven modelling where domain knowledge is needed, is indicative of the potential in ML methods but human expertise is still needed to attain even higher accuracy and precision.
The next stage after phenotype extraction is to create phenotype-genotype associations. In addition to the development of higher quality and more available electronic medical records, EHRs can now be matched with biopsies stored in biobanks through patient-specific identifiers making it possible to study genetic and phenotypic data alongside clinical findings. Earlier studies focused on using statistical methods, such as the proof of concept study done by Denny et al. to develop a method to scan phenomic data for genetic associations using ICD billing codes [16]. Subsequent studies have shown the viability of using ML algorithms to understand phenotype-genotype associations using EMR sources with most of the papers published in the past year [22, 23]. Recently, deep learning gained popularity as an accurate framework at identifying phenotype-genotype associations [24]. Boudellioua et al. takes a deep neural network and developed an OpenSource phenotype-based tool called DeepPVP, which prioritizes potential causative variants from whole genome sequence data [25]. As another example, Zeng et al. used Bayesian network learning to extract epistatic interactions, which are gene-to-gene interactions that change exhibited phenotypic traits, that effect breast cancer patient survival on 1981 EHRs taken from the METABRIC dataset [26]. Their model learned SNP associations that effect breast cancer patient survival that agreed with domain knowledge from breast cancer oncologists [26]. Furthermore, unsupervised learning has also been recognized as a great tool to discover new phenotypes [27]. Stark et al. studied the unsupervised extraction of phenotypes from cancer clinical notes to use in association studies and reported success in finding new phenotype-genotype association hypothesis that are not published but plausible from a biological perspective [27]. Positive results form many recent studies demonstrates how deep learning shows promise in phenotype-genotype association extraction.
Such high performing machine learning on big data to create phenotype-genotype associations give hope to the future of personalized medicine, which is healthcare tailored to different variations in a genotypes. More basic biomedical research on phenotype-genotype associations opens possibilities for selecting best treatments and for studying drugs that come back with negative or adverse results. However, getting to such advanced levels of drug research is still on the horizon as there are still more challenges in finding phenotype-genotype associations.
As mentioned before, one of the major problems is that EMRs generally suffers from the difficulty in identification and correction of missing or mistaken data. In many cases, ML methods require large datasets and when EHRs are amalgamated from multiple sources, a high number of varying kinds of errors are carried over to the data set and therefore propagate through to the algorithms. Due to the high throughput of data in ML methods, there is a need for an automatic correction filter, or a complete work around the missing data. One solution to missing EMR data is to identify the missing phenotype data and correct it using a combination of bioinformatics and genomic data [28, 29]. Even with sparse numbers of high quality phenotypic or genotypic data, there has been studies that have successfully extracted phenotype-genotype information from EMR using semi-supervised, bulk phenotyping framework, and NLP-based machine learning techniques [24, 30, 31]. Another method to tackle missing data is to use a machine learning model to completely encompass the missing data as part of the training set and therefore accept the sparsity as part of the valid data [32]. Another solution is to acknowledge the missing data as a variable in the modelling of the algorithm and quantify its predicted effects on the final results and conclusion [33].
In summary, EMRs are a vital source of information in basic biomedical science, specifically for phenotype-genotype associations, and there is a trend to test ML methods on this untapped and vast data set to overcome the challenges EMRs face during data mining. The advantage of EMRs is that it can be mined for phenotypes and linked to genomic data. The section discussed different types of standardized codes used in EMRs, which are easy to pre-process for ML frameworks. Codes such as ICDs, ICD-CM, and phecodes showed that they can successfully and conveniently identify phenotypes. However, standard codes used by providers were not intended for data-mining purposes and therefore see performance issues when they are used outside their primary objective, to identify phenotypes. To harness EMR data beyond codes, studies look at a mixture of ICDs and free text. In the context of phenotype identification, this blend of data sources showed high performance especially when using ML methods in conjunction with more rule-based methods that require domain expertise. Furthermore, this section discussed the strong viability of ML methods for phenotype-genotype association identification, with a trend toward using deep learning frameworks. EMR applications through ML methods still face the problem of missing or erroneous data, which may affect the subsequent biomedical conclusions. Further work is being done to combat the shortcomings discussed and overall, EMRs have proven to be a promising data source for phenotype-genotype related research.
Clinical research informatics has emerged in the last 5–6 years as a new field of biomedical translational research, which revolves around using informatics methods to collect, store, process and analyze real-world clinical data to further biomedical research purposes. With the increasing availability of such electronic data and the development of analysis tools, EMRs can help decrease the cost and time of clinical trials by automating patient recruitment, extend randomized control trials and enhance retrospective cohort studies.
Clinical trials are a crucial stage in drug development to test for drug safety and efficacy. These trials are time consuming, labor intensive and costly to operate, and a significant bottleneck for many trials is insufficient patient enrollment [34]. However, by harnessing the data contained within EMRs, clinical trials can become more efficient by automating recruitment and having a more extensive view of medical data compared to the traditional manual search. Successful examples have shown that EMR mining for potential recruitment are more cost efficient and less time consuming than traditional methods [35, 36]. As a quantitative example, a study done in the US studied 31 EHR-driven analysis on drug-to-genome interactions and concluded that EHRs helped decrease the trial cost by 72% per subject and reduced the duration of the studies [13].
It is also possible to repurpose systems that already exist within a clinical setting to improve trial recruitment. A study conducted by Devoe et al. repurposed an already existing Best Practice Alert (BPA) system, which was originally intended to improve patient care by automating basic keyword searches on patient EHRs, to recruit potential trial participants for a COPD study [37, 38]. Devoe et al. directly compared the cost effectiveness of the BPA-driven screening to that of the traditionally manual method, namely the EMR Reporting Workbench method where clinicians customize a query through a platform in order to pull data from the EHR database, and concluded that BPA was four times faster at screening all patients and ultimately lead to a projected 442.5 h reduction over the course of the study.
A particularly interesting case of a commercial EMR product developed for research purposes used in a clinical setting is a platform called InSite. This Software as a Service platform was developed out of the Electronic Health Record for Clinical Research (EHR4CR) project (completed Spring 2016), which aimed to create a secure, robust and scalable platform used around Europe to create a network of safe and security-compliant real world data, which can be reuse to further clinical research [39]. International research groups and medical providers from multiple countries developed this platform and intended for researchers to interact with hospital-based EHRs. A study by Claerhout et al. studied the feasibility of using InSite as a tool to estimate numbers of eligible participants for clinical trials at 24 European hospitals [40]. They studied the inclusion and exclusion (I/E) criteria of protocols from 23 trials across diverse therapeutic areas, including ABP 980 and trastuzumab for early breast cancer, a combination of cediranib and chemotherapy in relapsed ovarian, fallopian tube or epithelial cancer, and selumetinib in combination with docetaxel for metastatic lung cancer. These clinical trials were sponsored by various pharmaceutical companies 1 to represent key I/E criterion using terms included in the standard medical coding systems 2 [40]. It was found that a median of 55% of the I/E criteria can be translated to InSite queries using the standard medical coding systems to correctly identify potential trial patients. This result is promising as it shows the feasibility of translating the complex protocol criteria into machine-readable queries via an already existing platform.
This success of patient identification is attributed to how well defined the disease parameters are in the I/E criterion and whether its clinical concepts exactly match a query that the InSite platform can digest. Unfortunately, these queries do not contain easily accessible nor standardized temporal information on disease development such as the rapid progression of a tumor size or the timing at which an operation was carried out. This lack of temporal resolution led to the lowest formalization rate (38%) in patients with metastatic melanoma, revealing the difficulty of acquiring temporal information on tumor staging and genetic testing [40]. A possible next step to this study is to harness NLP to the unstructured EMR data and to resolve the temporal issue in order to increase performance in patient recruitment. Overall, this study showed the potential for this commercialized platform for optimizing recruitment by hospitals. Beyond the feasibility of estimating the number of potential trial patients, this platform is advantageous because InSite offers a convenient and efficient way for researchers can access real-time clinical data by extracting relevant EMRs without disrupting healthcare providers with new technological implementations.
It has been shown that NLP [34] is able to reduce the amount of manual-driven patient identification required. Once the number of patients eligible for a clinical trial is estimated, the next step is to carry out patient screening on each individual. There are three methods that can carry out these checks. Meystre et al. harnessed NLP to directly compare clinical trial screen accuracy between machine learning, rule-based and cosine-similarity based methods and reported the highest accuracy (micro-averaged recall 90.9%) and precision (89.7%) for the machine learning method [34]. In such automations, the usage of NLP and harnessing machine learning is key to fully automating cohort selections using EHRs, and there are research done to further those tools, which is illustrated with the emergence of CREATE [41] and SemEHR, which is an open source semantic search and analysis tool for EMRs [42]. Such automations revolutionize clinical trial processes by cutting down administrative work by an order of magnitude. To deal with the ever increasing amount of EMR data made available, case studies have also shown that unsupervised ML methods may be used to identify disease cohort selection with high accuracy compared to the traditional and manual methods [43].
In some cases, EMRs can allow for more diversity in clinical trials and provide data collection on individuals that are traditionally underrepresented, such as racial minorities, children, rural communities or pregnant women [35, 44, 45]. However, there are also studies that published poor performance of information retrieval through EMR and ML [46]. There are high expectations for a new wave of ML tools to revolutionize medicine but researchers must be vigilant for unexpected biases arising from ML models trained on skewed or bad data.
For an example of bias in EMR driven selection of patients for trial, we look at the work of Aroda et al. They compared EMR-driven recruitment for type 2 diabetes patient across multiple health centers in the US to that of the traditional manual method [47]. Although Aroda et al. reported that the EMR-based recruitment had higher numbers of patients screening, better performance and improved randomizations, they also noticed an association with fewer women and racial minorities recruited. EMR and electronic-driven recruitment may cause bias in the type of cohorts identified, as electronically visible individuals are more likely to be identified and then consent to trials. A skew in this electronic visibility allow only certain cohort groups to be identified and studied in a clinical trial [48].
These biases arising from ML models are a significant aspect of drug research as they may cause inadvertent negative effects when these technologies are brought to market and into the medical centers. This may be the case of poor data sets or a poor selection of algorithms. In the real world, catch-all algorithms that work in academia sometimes fail and sometimes there is just not enough data for the data-hungry machine learning methods. Since manual methods do not suffer due to lack of scale when ML-based and data-driven research fail when they cannot access big data, the rise of ML driven processes will not make manual ones totally obsolete.
Another potential for EMR is to extend short, cost-limited trials by electronically monitoring the cohort after the trial is over. This creates a long term follow up without the cost associated with a traditional, extended clinical trial. There has been a successful case in testing novel probiotics to carry out a 5 year follow up, which would have been too expensive in traditional methods and retention rate increased due to this electronic method [49]. Furthermore, EMR data may be used in clinical trials beyond just a follow-up. There is interest in using EMRs as a primary data source or as a feasibility assessment tool in observational clinical trials, comparative effectiveness studies and randomized clinical trials [50]. In addition, data can be used to carry out retrospective cohort studies or population based cohort studies. Kibbelaar et al. proposed a method to combine data from population-based registries with detailed EHR to conduct an observational study and reported on a case study in an hemato-oncology randomized registry trial [51].
These implementations are dependent on the patient’s consent to partake in the trials and there are studies that investigate the process and ethics of such consent [52]. Beskow et al. identified patient informed consent as a bottleneck in using EHR for randomized clinical trials. A study has also identified gaps in ethical responsibility in clinical studies carried out [53]. Furthermore, compliance to security and privacy regulations is a critical challenge as clinically produced EMRs proliferate through cloud platforms, mobile devices and commercialized technology. Whilst security and data protection are of paramount importance when dealing with EMRs, a discussion of the methods currently in use is beyond the scope of this chapter. The reader is directed to Refs. [54, 55, 56], in which the current technologies and methods used for security measures on EMRs are reviewed.
To conclude, using data within EMRs can help decrease the cost and time of clinical trials. First, the section discussed successful examples of EMR mining for potential recruitment in clinical trials, which included using systems that already exist in clinical settings, such as BPA and InSite, and tools that employ ML methods. An advantage with the use of ML methods in clinical trials is the increase in diversity in trial patients but there is still an issue with the bias that cause inequality in patient selection. Ultimately, the quality of the ML approach depends on the quality of the training data. Therefore, with access to excellent data, EMRs can be used to extend short, financially limited trials or used as a primary data source to carry out aspects of data-driven clinical trials. Whilst ML methods are showing strong performance in enhancing clinical trials, big challenges remain before the data-driven method replaces the current clinical methodology.
However thoroughly a new drug is trialed and tested before it enters the market, it is possible that there are unknown adverse drug events (ADEs, colloquially known as side-effects) that manifest on time scales or in ways that cannot be seen in a clinical trial. Currently, adverse side effects of pharmaceutical products are a significant source for morbidity and are a significant healthcare cost in many countries [57, 58]. Therefore, it is vital that pharmaceutical companies undertake pharmacovigilance, in which they continually track the effects of their drugs after the drugs deployment. This means that clinical data on post-market drug effects has a high value to pharmaceutical companies [59]. Post-market surveillance of drugs to detect, evaluate and prevent ADEs with licensed drugs released in the market is called pharmacovigilance and is imperative for decreasing negative drug incidents.
Traditionally, medical professionals with domain knowledge would manually identify ADEs through sources such as clinical trials, health reports, published medical literature, observational literature and social media [60], which is time consuming and costly. Therefore, automatically mining these electronic narratives are an efficient way to identify negative events in the real world setting. Luckily, real world data on pharmaceutical products and their effects are richly logged in patient EHRs. To successfully mine the vast quantity of dense data in the EHRs for drug events, specifically ADEs, studies have focused on the narrative aspect of EMR and have successfully extracted ADE from both structured [61, 62] and unstructured [63, 64, 65] texts.
This focus on EHR narratives stems from studies that have shown that disease classification codes, such as ICD, used in EMRs do not encompass the symptoms, disease status and severity needed for ADE sensitivity and therefore are not appropriate in drug event mining [66, 67, 68]. Therefore it is necessary to extract more detailed information from the written text in EMRs, which is achieved using NLP algorithms. This is a two staged computational task. Firstly, the algorithm must perform accurate name entity recognition (NER) to identify diseases, drugs, and negative events in the text, and then it must quantify associations between those entities, to build a concept of what had occurred [69, 70].
Since 2012, significant developments in statistical analysis, machine-learning methods and heterogeneous data integration have allowed for automated ADE detection and offer tools for a novel, automated pharmacovigilance analytics [71]. Some statistical methods such as the odds ratio has been used by Leeper et al. and Banda et al. to create algorithms designed for extracting drug–ADE associations from EHRs [72, 73]. However, due to the need to define hypothesis using domain knowledge, experts in the field were necessary and this suggests a limitation that these statistical frameworks will not necessarily benefit from having more access to EHR resources because the core predictors depend on a priori knowledge, which is static within the algorithm. This means that there is currently still a manual element required in the process, which limits the scalability of this approach.
Some of the early EMR-narrative studies focused on keyword and phrase driven identification of general ADE. For example, there are semantic searches specializing in certain disease targets such as the work done by Ferrajolo et al. who looked at drug related acute liver injury [74, 75] and Pathak et al. who mined for DDI between cardiovascular and gastroenterology pharmaceutical products [76, 77]. Although these disease specific searches may increase ADE detection in a certain medical domain, this tailored approach is not scalable or translatable to other diseases. In terms of identifying general ADEs without a target disease, Honigman et al. developed a search method using the Micromedex M2 D2 (Micromedex, Denver, Colorado) medical data dictionary to semantically associate drugs and drug classes to their negative effects and successfully showed the viability of keyword searches on EMRs [78, 79]. Chazard et al. went a step further to demonstrate searches on a variety of data structures such as drug administration records, laboratory results, and other clinical records to successfully detect general ADEs within free texts [80, 81]. These previous methods successfully identified general ADEs, but keyword driven searches are now considered simplistic and not scalable, but the success of even that method shows that there is great promise for modern techniques.
A further development to keyword-based semantics is a more symbolic rule-based search that looks for semantic patterns around drug and ADE entities. These symbolic rule-based searches allow for more information on dosage and non-standard terminologies to be identified during queries and are more capable of general ADE recognition [82, 83, 84, 85]. With the rise of semantic research in the medical space, biomedical NER and NLP has been developed to aid clinical semantic searches and there are several open sources available, which have been adapted for ADE identification such as MedLEE [86], MetaMap [87], cTAKES [88, 89], MedEx [90], and GATE [91]. Of those, MedLEE and MetaMap are two of the most widely used, particularly in the pharmacovigilance space, where researchers extract Unified Medical Language System (UMLS) concepts from texts using NLP based approaches. Studies have shown the adaptability of these already available NLP systems. Banerjee et al. used grammar rules to extract all noun entities and then used MetaMap to semantically identify the type of entity found. This study found that medications are easily found as entities, but the model had difficulty in extracting symptoms from laboratory test results as they vary in length and word choices [92]. In adapting these NLP systems, each study hit limitations of each source and in particular these tools are not very capable in temporal resolution, which makes it difficult to distinguish drugs that cause ADEs from those products that indicate the presence of an ADE.
This shortcoming in temporal resolution has pushed for another wave of studies. In understanding the use of medication and mentions of diseases, the context surrounding these entities will determine whether the drug was or was not used at a time before or after an adverse incident. Some studies have created time stamps on event entities and medication administration in order to exclude situations where the adverse symptom was an already existing condition at drug administration, the ADE was due to another drug, the drug did not cause the ADE and is mentioned as a negative association, or the pharmaceutical product was given as treatment to the ADE [84, 93, 94]. Although time resolution on ADE events increase the accuracy of adverse incident detection, the vagueness and implicit tendency in the human language to describe temporal events remain as bottlenecks [95].
A great example to illustrate a collaborative ML research on clinical EMRs is the MADE1.0 challenge carried out in the US. This ML challenge illuminated the popularity and effectiveness of deep neural networking learning in identifying negative drug incidents, as these models counted for most submissions to the competition.
In the US, death due to a drug incidence is one of the top six causes of death with around 2–5% of hospitalized patients suffering from ADEs; in each case an adverse event can increase healthcare cost by more than $3200 [96]. Traditionally, ADE-based pharmacovigilance is done by domain experts reading information on causality of drugs on incidents and temporal data on these events buried in the clinical narrative. However, this manual method is not scalable and very costly. To tackle the significant health and financial strain caused by ADEs, US research institutions participated in a machine learning challenge to develop methods automate real-time drug safety surveillance.
In 2018, University of Massachusetts (UMass) hosted a public NLP challenge to detect Medication and Adverse Drug Events from Electronic Health Records (MADE1.0). UMass provided 1092 longitudinal EHR notes, which were anonymized from 21 cancer patients from the University of Massachusetts Memorial Hospital. This EHR resource was rich with information on diseases, symptoms, indications, medications and relationships between these entities. Three main tasks were defined in this challenge: (1) named entity recognition (NER), which extracts drug medications, their attributes (dosage, drug administration, duration, etc.), disease indications, ADEs and severity, (2) relation identification (RI), which creates associations between entities, namely drug-indication, drug-ADE, and medication-attribute relations, and (3) the joint task that assess the NLP model’s ability to perform both NER and RI. More detailed information on the challenge can be found at [96]. Jagannatha et al. reported that out of the 11 participating teams the highest F1 scores in each category was 0.8290 in NER, 0.8684 in RI, and 0.6170 in NER + RI, where the F1 score is the weighted mean of precision and recall with ranges from 0 (worst) up to 1 (best) [97].
Within NER task models, the main task can be distilled down to tokenizing sentences, so the tokens can then be labelled as specified entities. One common framework for NER is the hidden Markov model (HMM), in which the system is assumed to be the product of an unknown Markov process, which can then be statistically modelled. Conditional random fields (CRFs) are related to HMMs, however they differ in that, unlike HMMs, they are discriminative and classify labels by drawing decision boundaries. Unlike HMM, CRF does not have strict independence assumptions, which makes the model more flexible but highly complex at the training stage, meaning that retraining is more involved than that of the HMM [98]. The other main class of model is the neural network, including convolutional neural networks (CNN) and recurrent neural networks (RNN). Long short-term memory (LSTM) is an RNN architecture in common use for NER purposes. It is designed for classifications and predictions on time series data, in which events may occur with significant and unknown time lags in the sequence [99]. Teams involved in the MADE1.0 challenge used pre-trained embeddings to prepare the RNNs or as feature inputs into CRF training [97]. Within NER task models in this challenge, conditional random fields (CRF) and long short-term memory (LSTM) were among the most frequently used frameworks [97].
In the NER category, team WPI-Wunnava scored the highest scores with F1 = 0.8290 [97]. Wunnava et al. created a system called the Dual-Level Embeddings for Adverse Drug Event Detection (DLADE) to tailor to the NER task [100]. In the challenge, the NER task is limited to certain standard resources like NLTK, Stanford NLP, and cTakes for the text pre-processing for fairness of the participants with varying accessibility to resources. In particular, DLADE used training data and word embeddings provided by the challenge organizer as part of the publicly released resources. Wunnava et al. developed the system with a rule-based tokenizer, which first tokenized sentences, and then entities within sentences, where entities may be multiple words. The system then uses a combination of bi-LSTM, a model that examines the text sequence in the forward and reverse direction to extract contextual representation, for the initial two layers responsible for the character embedding and the word embedding but employed a linear-chain CRF for the output layer [100]. Wunnava et al. concluded that their dual-level character and word embedding method was a better approach compared to the simple word-embeddings by showing a statistically significant (p < 0.05 and p < 0.01) improvement in F1-score over multiple entities (ADE, drug, dose, duration, etc.) [100]. However, many challenges remain when identifying multi-worded entities, unknown abbreviations, ambiguous differentiation between entities such as indication vs. ADE, and uses of colloquial or non-medical jargon.
In both the RI and NER-RI tasks, the process can be simplified to a classification problem, where entity pairs are in a certain class of relationships. Research teams used a variety of approaches to the RI tasks. As well as neural network methods, they also used random forest classifiers, in which an ensemble of decision trees is used and the aggregate score from the committee of decision trees decides the output class. Support vector machines (SVM) were another popular tool; they are optimizing algorithms that maximize the margin between the support vectors (input data) and the decision hyperplane [101].
In the RI category, team UofUtah-Patterson score the highest scores with F1 = 0.8684 [97]. Chapman et al. treated the RI task as a two-step supervised classification problem and employed random forest models implemented on scikit-learn to identify true relations between entities and to class the type of relation of the identified pair [102]. Their source code for their models submitted to the MADE1.0 challenge can be found on their github page [103] and details on the model architecture is authored at [104].
In the NER + RI category, team IBMResearch-dandala obtained the highest integrated task score (F1 = 0.6170) by harnessing bidirectional long short-term memory (BiLSTM) and CRF neural network for medical entity recognition, and a combined BiLSTM and attention network for relation extraction [97]. Dandala et al. reported that NER was achieved at high accuracy (F = 0.83) and RI measured an F score of 0.87 achieved by adding joint modelling techniques and using external resources as extra data inputs [105]. However high the individual F score, the overall integrated task only reached 0.6170, which suggests the need for domain knowledge to increase accuracy in ADE detection.
The MADE1.0 challenge highlights the potential for developing pharmacovalidation based on ML methods with very high performance in categories such as NER and RI, which are crucial in automated ADE extraction from EMRs. At the time of completion of the MADE1.0 challenge, Jagannatha et al. suggested two broad approaches to further improve the challenge’s outcomes [97]. First, to work on designing methods that include external knowledge and unlabeled text, which suggests the potential for unsupervised learning. The second point was to increase efforts in higher volume, labelled corpus to train the models on, but this does not solve the issue of algorithms failing to adapt to the messy, real world EHRs, an inevitable encounter in commercial use. Not only did this challenge show success in developing ML-based pharmacovigilance but also demonstrated the power of collaboration and influenced other groups to further ADE research.
After the MADE1.0 challenge, an even further increase of available EHR resources has pushed researchers to develop robust ML methods, which are inherently data hungry and are predisposed to the vast amount of information provided by clinical texts. There is a study that builds on the MADE1.0 challenge and shows the potential for deep learning models on EHR to extract ADE measures to help with pharmacovigilance. To try to solve the issue of under-reporting within the FDA Adverse Event Reporting System, Li et al. employed deep learning models and multi-task learning (MLT), in particular, hard parameter sharing, parameter regularization, and task relation learning, for ADE detection [106]. They used the MADE 1.0 challenge corpus, 1089 high-quality EMRs from oncology patients, for training and validation of their model. A BiLSTM conditional random field network was used for entity recognition and a BiLSTM-Attention network for entity relation extraction. Li et al. reported that the deep learning produced a F1 = 0.65 for the NER + RI task and this score was further improved through the hard parameter sharing MLT method to F1 = 0.67, whereas the other two MLTs did not improve performance. This study successfully built upon the findings from MADE1.0 and further improved the performance of the NER + RI task to show potential in this area.
Some ML trends that extract medically actionable results are the popularity of CRFs, SVMs, and random forest models. CRFs and SVMs may be used on languages beyond English. For example, Aramaki et al. studied Japanese clinical records and found that ADE were found in 7.7% of EHRs, out of which 59% can be automatically extracted [107]. They used CRFs and SVMs to determine whether a detected drug and adverse event pair was an ADE, which gave a 0.411 precision and 0.917 recall. In contrast, random forest models have been popular due to its reliable performance and explainability of the classifications when compared with other “black-box” models such as SVMs. Studies by Henriksson et al. and Wang et al. has used random forests for classification of entities and identify ADEs [108, 109]. Explainability of models is an often undervalued aspect of ML, but is valuable in the medical space. Overall, despite the many challenges, data-driven pharmacovigilance has advanced at an incredible pace owing to the mixture of funded challenges and developing ML methods and shows much promise to improve healthcare.
It is worth mentioning that EMR data can be mined for drug repurposing indications. The idea behind drug repurposing is to see whether existing, licensed drugs may have therapeutic benefits for conditions other than what they were designed for. Data-driven analysis is evidently key in this regard as it can detect drug response signals. Drug repurposing is different from the traditional drug discovery because data-driven analysis lacks a hypothesis for the indication intended to be treated or for the targeted biology. In other words, studies examine machine learning methods to see whether data-centric analysis can help create new hypothesis, which may either be a completely random and biologically impossible statement or a novel signal worthy of scientific investigation. Since drug repurposing only needs medical data and analytics, it is a cheap and quick alternative to the traditional drug discovery stages, which require basic research, pre-clinical research, clinical trials, and finally the review and approval of the pharmacogenomic product. The potential of drug repurposing is highly anticipated as this method requires big data and an increasing amount of digitized medical records such as EHRs are made available. It is a particularity popular topic in recent years as data-hungry machine learning tools develop and high-throughput server less machines are made cheaper and more accessible through cloud computing services such as AWS, Google Cloud Platform, and Microsoft Azure, to name a few. For a more in-depth discussion of oncology drug repurposing using data from EMRs, the reader is directed to Refs. [110, 111, 112].
Another anticipated but still young area is the possibility of precision medicine using individual genomic data. Cancer is an accumulation of genetic alternations within the cell and, oncogenetic or cancer-developing genes are called driver genes. Identifying driver genes within the genome and delivering the optimal treatment to such cancer-related targets is known as precision medicine. However, there is a vast amount of data within even a single individual’s genome and finding variants becomes the key challenge in order to pinpoint the best pharmacological treatment for an individual based on their genetic background. Harnessing the combination of data from already existing genomic variant databases and historic clinical data from EMRs, researchers aim to find such cancer-related variations and driver genes. In a few countries, studies revolving around the interaction between the genome and cancer treatment drugs have gained much attention.
In the US, the NCI-MATCH trials, a phase II precision medicine cancer trial initiated in 2015, showed negative results in precision medicine and concluded that the genomic data did not correlate with any significant results in drug variation [113]. This low statistical significance is not surprising from a data mining perspective as numbers of patients accrued for each of the +40 arms within this study were very small, ranging from 4 to 70 people [114]. Furthermore, the majority of the recruited patients (62.5%) had rare tumors that were not the four most common cancers (breast, colorectal, non-small cell lung, and prostate) [115]. This diversity in cancer types may have introduced confounding factors that affected the statistics of the trial.
In Japan, starting 2018, the Japanese Ministry of Welfare and Labor is sponsoring a panel trial on partial genomic testing for oncogenetic variation. This partial genomic testing aims to reveal the best and optimal cancer drug treatment on the individual based on their genetic variations. In 2019, 11 Cancer Genomic Core hospitals and central medical institutions were selected to start collecting genomic data and clinical data in preparation for a nation-wide genomic panel trial [116]. Under the funding of the country’s National Health Insurance, it strives to predict cancer patient treatment responses based on their partial genome data.
There is a complex interplay between intricate biological systems and the NCI-MATCH trial illustrates that precision medicine methods need much more development before they can pin point a certain genomic sequences to the onset of cancer. Some have voiced pessimistic views that this precision medicine task is not feasible and overly-costly at this point in time [117]. However, precision medicine is in the horizon. With more data samples, similar research can yield more insight into precision medicine.
In the future, individual whole genome data may be regular practice to include as part of EHRs in order to help deliver the optimal cancer treatment. Currently, there is a bottleneck where there are not enough types of commercialized cancer drug against which to test the genomic variation and to find which treatment works best on an individual. As all aspects of EMR-driven research converge, more medical data will be collected, stored and published. This will lead to already available commercial drugs undergoing more comprehensive pharmacovigilance and real-world data will effectively drive new drug research. Therefore, it is likely that more types of cancer pharmacology products will become available. Furthermore, the efforts in using ML to mine EMRs may lead to AI predicting cancer patient disease trajectories. The trend toward using NLP to extract relevant information from unstructured EMRs and harnessing deep learning could help reproduce drug-related clinical decision making carried out by medical professionals [110, 111].
In England, there are trusts and clinical commissioning groups who oversee how providers such as hospitals and clinics use their resources. A problematic bottlenecks are that different trusts use different EMR platforms, which have little national standardization and do not allow for interprovider access, which especially cause problems when patients switch trust domains.
A remedy to this lack of standardization is the use of open sourced, publicly available resources including de-identified EMR data. Evident from the data-hungry nature of ML methods and their demonstrated need in scalable phenotype-genotype association research, publicly available EMRs play a crucial role in the advancement of this field. Some notable open sourced data sources and tools include the UK Biobank, where 50,000 individuals (aged 40–69) were recruited from England, Wales, Scotland [118]. The biobank includes detailed phenotype and genotype data, lifestyle surveys, pathophysiological data and imaging data on each individual [118]. Once a centralized, open-sourced EMR data is made available, the next step is the development of platforms that interact with said resource.
The CArdiovascular disease research using LInked Bespoke studies and Electronic health Records (CALIBRE) portal offers freely available software that provides tools and algorithms, which is research ready and have already extracted variables extracted from various EMRs. Phenotype algorithms contained in CALIBRE, which employs data from the UK Biobank, are rule based and use phenotype validations like etiological, which use external published evidence to support the algorithm; prognostic, which evaluate the event’s similarity to already existing scientific knowledge; case-note review, which compares the positive predictive value (PPV) and the negative predictive value (NPV) against a gold standard like a clinician’s notes; cross-EHR-source concordance, which checks the consistency in findings across other EHRs; genetic, which double checks whether there is consistency in genetic associations and external populations, which validates by comparing results to similar studies done in different countries [119]. These phenotype validations, and standardized validation systems in general, are crucial in characterizing ML algorithms since variations in training data can alter outputs even when the ML method does not change. As open source data proliferates, freely available validation methods may grow in a parallel manner.
In addition, openEHR is also a platform that pools industry specifications, clinical models and software that are intended for data science solutions in the healthcare space. OpenEHR was founded in 2003 by an international non-profit organization and maintained by individuals around the world [120]. In 2017, the UK became the first country to introduce infrastructure from openEHR into the main healthcare system to streamline phenotype data collection and vendor-neutral clinical data storage from all the trusts participating in the 100,000 genome project [121]. Newly coordinated pipelines of additional EHR data such as those from the NHS will increase the through-put in openEHR, which in turn develops the best tools to handle big data, which then completes the circle by promoting the use of an ever increasing amount of medical data. This data-driven vision, in which an open community encourages cooperation by open access and pools existing knowledge around EMR-driven healthcare, will certainly accelerate the evolution of ML methods.
Estonia is one of the world-leading countries in terms of the nationwide systematization of digital medical documentation and the high quality of EHRs. By the end of 2014, Estonia had centralized EHR access via a single portal, where over 99% of the population could view their own medical records [122]. This is a remarkable statistic but more notably, Estonia’s EHR vision had already been initiated in 2007 when the Estonian Genome Center of the University of Tartu established the foundations of the Estonian biobank, which includes 52,000 participants worth of genomic and health data representing about 5% of the adult population of Estonia [123, 124]. Seven years later, the Estonian biobank was linked to the Estonian National Health Information System (ENHIS), which included 44,000 inpatient and 212,000 outpatient medical summaries, EHRs and digital prescriptions from all medical service providers [124]. Since the merge, the databases have been updated through periodic additions of EHRs. By 2016, Estonia was ranked within the top three countries to have the best capability of effectively deploying, operating, maintaining and supporting statistical and medical research using EHRs by the HCQI Survey of Electronic Health Record System Development and Use [125]. This extensive data collection was made possible by the national electronic identification card (ID-card) as this chipped ID-card was made compulsory and became part of the national infrastructure [126]. As result of these efforts, Estonian EHR databases are highly valuable sources for researching EHR-driven methods.
An ADE study using Estonian EHR databases by Tasa et al. demonstrates the database’s ability to conduct high impact, translational research. The whole-genome sequencing (WGS) data of +2200 Estonian Biobank participants and the EHRs of the sequenced individuals were taken from Health Insurance Fund Treatment Bills, Tartu University Hospital and North Estonia Medical Center databases [127]. EHRs were mined using ICD codes to find ADE occurrences and a mixture of the ICD and manual verification methods was used to identify associations between genetic polymorphisms and ADEs [127]. Associations between genetic variations and drug responses are vital in advancing personalized drug treatment, which is also referred to as pharmacogenomics. Important genes within the study of pharmacogenomics are called pharmacogenes. The study reported 29.1 × 106 novel variants. To priorities genetic analysis, Tasa et al. compiled 1314 loss-of-function, missense, and putative high-impact variants in promoter regions of 64 pharmacogenes [127]. They reported that 80.3% of the variants were rare (MAF < 1%), and this high proportion suggests that gene variation is crucial in understanding pharmacogenomics [127]. Next, the study combined EHRs to the genetic data to extract 1187 participants with potential ADEs. As a validation, Tasa et al. replicated pharmacogenetic associations between the CYP2D6*6 allele and tramadol related ADEs (p = 0.035; odds ratio [OR] = 2.67) and between the same allele and amitriptyline induced ADEs (p = 0.02; OR = 6.0) [127]. In addition, they replicated four more validated pharmacogenetic associations and discovered nine independent, new gene associations with ADEs in a group of individuals divided by drug prescriptions. Notably, they identified a new association between CTNNA3 and myositis for oxicam-treated participants. This study demonstrated the viability of layering EHR and WGS data at a population-based scale in order to advance pharmacogenomic. Beyond the scope of this study, identifying pharmacogenomic associations relies more and more on big-data driven projects that looks for genetic variants in different communities and highlights variants that can be medically targeted to advance healthcare [128, 129, 130].
In summary, Estonia’s world-leading efforts to integrate EHRs as a method to feedback data to basic research is a possible future of data-driven healthcare medicine, which focuses on digitization with a vision for translational biomedical research. Estonia created a data-mining driven database, in which different aspects of the EHRs are linked an ID-card. Although different implementations will be necessary to replicate Estonia’s rich and accessible EHR database, Estonia sets a precedent to the rest of the world and demonstrates the positive biomedical implications of such well-organized databases of rich EHR sources.
In the past decade, EMRs have become a vital data source in advancing healthcare. In the context of AI, EMRs are highly attractive because there is a vast quantity of rich and variable data types which cannot be processed manually. In the context of biomedical research, EMRs have exciting potential for impactful medical applications, but only if actionable biomedical conclusions can be accurately extracted. In the clinical context, EMRs were introduced to replace the traditional paperwork but were not intended for data-mining research; they were never intended to perform anything that paper documents were not designed to do. Having been introduced in a time before the phrase “machine learning”, digitization of medical records has far surpassed the imagined benefits of this transition. Envisioned as a direct replacement of paper records, EMR history has been fraught with difficulties: implementation costs, workflow disruptions and cyber-attacks to name a few. Harnessing EMRs for research purposes marks a milestone in translational biomedical medicine. It is the intersection of basic science, data-driven methods and clinical research where healthcare is transformed: every hospital visit improving human knowledge of diseases one EMR at a time.
The chapter started with a discussion of the EMRs definition, given that they have been introduced with little regard to compatibility with other existing EMR systems. There are many issues that hospitals can encounter when transitioning from paper records to electronic, however, efficiency gains from digitizing records are significant even without the use of big data. To exemplify what can be achieved by applying ML techniques to the data contained in EMRs, three key biomedical research areas were considered: phenotype-genotype association, clinical trials for new drug and pharmacovigilance studies.
Adopting high throughput data strategies into clinical drug trials can reduce the inefficiencies that often plague such trials. EMR mining using already existing systems can improve trial recruitment, but care must be taken to reduce potential bias in patient selection. Additionally, EMRs can be employed to continue data collection after the trial formally ends, a great benefit for financially limited trials, or they can even be treated as a primary data source as long as the data is considered to be of satisfactory standard.
After a drug undergoes clinical trials and is approved for market launch, pharmaceutical companies are encouraged to continue drug surveillance to detect, evaluate and prevent adverse drug events, which create medical and financial burdens. Such surveillance can be cheaply and efficiently done by continually mining EHR narratives. In the context of ADE detection, keyword searches are considered to be too simplistic and to lack scalability. Despite this, they still show some success in small scale studies, serving as a proof of concept that harnessing EHRs with more advanced processes could greatly benefit pharmagovigilance. However, NLP based-approaches performed much better than keyword-based methods and an excellent case study on NLP-driven pharmacovigilance is the MADE1.0 challenge. By bringing together multiple institutions, the challenge succeeded in developing high performing ML methods, including frequent usage of CRFs and LSTM, for the NER and RI tasks. This initiative promoted further works to create even more robust ML methods to extract ADEs from oncology EMRs and reflects the overall trend in the pharmacovigilance space toward CRF, SVM and random forest models.
With this vital context on how ML methods are used to analyze the data within EMRs, some selected international case studies on EHR-driven research were presented. Firstly, on the outlook of oncology precision medicine: NCI-MATCH trials in the US concluded that no drug response is correlated with genomic data, whilst preparation for partial genomic testing for oncology drugs is underway in Japan. Despite negative results nation-wide initiatives may spur on the collective development of drug research. Secondly, UK-based open source resources for EHR manipulation, were discussed, both large consolidated datasets and freely available tools, algorithms and platforms. This vision for open sourced resources is a valuable digital environment in which to pool technical knowledge, especially because of the translational and multi-disciplinary dimension of extracting medically meaningful conclusions from EHRs. Thirdly, the EHR databases set up in Estonia were reviewed, which are both nationally extensive and high quality. This set up the groundwork to deploy a population-based WGS and EHR combinatory study conducive to pharmacogenetic advances. Estonia’s databases demonstrate the power of harnessing data from EHR for the progress of healthcare.
In contrast to the recent advancement and current interest in clinically-applied deep learning, there is still no definitive evidence of a model with predictive performance that is similar to a human physician [131]. As of 2020, there is no immediate vision in which AI can fully automate drug research pipelines or independently diagnose and provide subsequent health care procedures making researchers and clinicians obsolete. As we have seen, however, there is ample evidence that EMRs will increasingly play a vital role in all aspects of the drug research arc from fundamental science and clinical trials to post-market surveillance.
The author declares no conflict of interest.
EMR | electronic medical record |
EHR | electronic health record |
NHS | National Health Services |
ML | machine learning |
DDI | drug–drug interaction |
ADE | adverse drug event |
ICD | International Classification of Disease |
WHO | World Health Organization |
ICD-CM | ICD Clinical Modification |
SNP | single nucleotide polymorphism |
CNN | convolutional neural network |
I/E criteria | inclusion and exclusion criteria |
NLP | natural language processing |
HMM | hidden Markov model |
CRF | conditional random fields |
RNN | recurrent neural networks |
LSTM | long short-term memory |
BiLSTM | bidirectional long short-term memory |
NER | named entity recognition |
RI | relation identification |
SVMs | support vector machines |
CALIBRE | CArdiovascular disease research using LInked Bespoke studies and Electronic health Records |
WGS | whole-genome sequencing |
Biometric identification has been widely applied in modern society, such as electronic payment, entrance control, and forensic identification. As a reliable solution for identity authentication, biological characteristics refer to the inherent physiological or behavioral characteristics of the human body, including the iris, pattern, retina, palmprint, fingerprint, face and also voiceprint, gait, signature, key strength, etc. In the last decade, we have witnessed the successful employment of recognition systems using fingerprint, iris, and face. With the development of image capture devices and recognition algorithms, palmprint recognition receives more and more attention recently. Palmprint image contains principal lines, wrinkles, ridges, and texture that are regarded as useful features for palmprint representation and can be captured with a low-resolution image [1]. Palmprint recognition has several advantages compared with other biometrics: (1) the line features and texture features in a palmprint are discriminative and robust, which can be easily fused with other hand features (dorsal hand vein, fingerprint, finger knuckle); (2) the pattern of palmprint is mainly controlled by genetic genes, when combined with palm vein information it can achieve high antispoof capability; (3) palmprint image acquisition is convenient and low-cost, and a relative low-resolution camera and a light source are sufficient to acquire the images; (4) the palmprint acquisition is hygienic and user friendly in the real applications. Based on the custom acquisition devices, more information can be retrieved in a multispectral image or 3D palmprint image. A 2D gray scale palmprint example with feature definitions is shown in Figure 1. The purpose of this chapter is to review recent research on palmprint acquisition systems to trace the development of palmprint recognition-based biometric systems. In this chapter, we coarsely divide the devices into three types by acquisition mode: touch-based devices, touchless devices, and portable devices. Touch-based devices usually have pegs to constrain the hand pose and position, which can capture the details of palmprint to the most extent. The illuminating environment is also stable during capturing process. These constrains ensure the captured palmprint images to be high quality. For touchless devices, users can freely place their palms in front of the camera while the hand pose is generally required to spread out the fingers. The environment during the capturing process becomes more complicated, especially the illumination. There are also datasets composed of palmprint images captured in a relatively free fashion. These images may be collected on the Internet which we will not discuss here. Otherwise, collectors use digital cameras or phone cameras to capture palmprint image, and usually, there are no strict conditions forced on the user. In the rest of this chapter, first, we will introduce the representative palmprint acquisition devices, and then study the relationship between the palm distance, image sharpness, hardware parameters, and the final recognition performance. Table 1 summarizes the palmprint acquisition devices.
Palmprint images and feature definitions.
Ref. | Year | Device type | Image type | Description |
---|---|---|---|---|
[1] | 2003 | Touch-based | Gray scale | Adopt low-cost camera to capture low-resolution image palmprint; use pegs as guidance |
[2] | 2007 | Touchless | RGB and IR | Realize noncontact capturing of palmprint images under unconstrained scenes |
[3] | 2008 | Touchless | RGB | Capture palm in real-time video stream using skin-color thresholding |
[4] | 2009 | Touch-based | 3D | Acquire depth information in palm using structured light imaging |
[5] | 2010 | Touch-based | Multispectral | Propose an online multispectral palmprint system |
[6] | 2010 | Touchless | RGB and IR | Capture palmprint and palm vein images simultaneously |
[7] | 2011 | Touch-based | Gray scale and IR | Capture palmprint, palm vein, and dorsal vein images simultaneously |
[8] | 2012 | Portable | Gray scale | Use different portable devices to capture palmprint images |
[9] | 2012 | Touch-based | Gray scale and 3D | Acquire 3D information and 2D texture in palm |
[10] | 2015 | Touchless | RGB | The RGB’s blue and red channels are processed separately for bimodal feature extraction |
[11] | 2016 | Touch-based | Gray scale | Develop a line scanner to capture palmprint images |
[12] | 2017 | Touch-based | Gray scale | Proposed a novel doorknob device to capture the knuckle images |
[13] | 2018 | Touchless | Multispectral | Capture palmprint and palm vein images in the device; established the current biggest publicly available database |
The palmprint recognition systems.
Reference [1] is a pioneer work for palmprint acquisition and recognition that builds the first large-scale public palmprint dataset. The captured palmprint images are low-resolution with 75 pixels per inch (PPI), so that the whole process can be completed in 1 s, which achieves real-time palmprint identification. The palmprint capture device includes a ring light source, charge-coupled device (CCD) camera, a frame grabber, and an analog-to-digital (AD) converter. Six pegs are serving as control points that constrain the user’s hands. To guarantee the image quality, during palmprint image capturing, the device environment is semiclosed, and the ring source provides uniform lighting conditions. After capturing the palmprint, the AD converter directly transmits the captured images by the CCD camera to a computer. The well-designed acquisition system can capture high-quality images, which boosts the performance of the identification algorithm. The experiment result also demonstrates that low-resolution palmprint can achieve efficient person identification. Our palms are not pure planes, and many personal characteristics lie on the palm surface. From this view, 2D palmprint recognition has some inherent drawbacks. On one hand, much 3D depth information is neglected in 2D imaging. The main features in 2D palmprint are line features including principal lines and wrinkles, which is not robust to the illumination variations and contamination influence. On the other hand, the 2D palmprint image is easy to be counterfeited so that the anti-forgery ability of 2D palmprint needs improvement. For capturing depth information in palmprint, [4, 14] explores a 3D palmprint acquisition system that leverages the structured light imaging technique. Compared to 2D palmprint images, several unique features, including mean curvature image, Gaussian curvature image, and surface type, are extracted in 3D images. Many studies have proposed different algorithms that encode the line features on the palm surface; however, the discriminative and antispoof capability of palm code needs to be further improved for large-scale identification. To obtain more biometric information in the palm, in [5] a multispectral palmprint acquisition system is designed, which can capture both red, green, and blue (RGB) images and near-infrared (NIR) images of one palm. It consists of a CCD camera, lens, an A/D converter, a multispectral light source, and a light controller. The monochromatic CCD is placed at the bottom of the device to capture palmprint images, and the light controller is used to control the multispectral light. In the visible spectrum, a three-mono-color LED array is used with red peaking at 660 nm, green peaking at 525 nm, and blue peaking at 470 nm. In the NIR spectrum, a NIR LED array peaking at 880 nm is used. It has been shown that light in the 700 to 1000 nm range can penetrate the human skin, whereas 880–930 nm provides a good contrast of subcutaneous veins. The system is low-cost, and the acquired palmprint images are high-quality. By fusing the information provided by multispectral palmprint images, the identification algorithm achieves higher performance on recognition accuracy and antispoof capacity.
Touch-based devices can easily capture high-quality palmprint images which contribute to high performance in person identification, while their drawbacks also lie in this acquisition mode. Firstly, users may have hygienic concerns since the device cannot be cleaned immediately. Secondly, some users may feel uncomfortable with the control pegs and constrained capture environment. Thirdly, the volume of the device is usually larger than palm, which causes problems of portability and usability. As the first attempt to solve the above issues, [2] presents a real-time touchless palmprint recognition system, and the capture processes are conducted under unconstrained scenes. Two complementary metal-oxide semiconductor (CMOS) web cameras are placed in parallel, one is a near-infrared (NIR) camera, and the other is a traditional red green blue (RGB) camera. A band pass filter is fixed on the camera lens to eliminate the influence of NIR light on the palm. The two cameras work simultaneously, and the resolution of both cameras is 640 × 480. For further hand detection process, during the image capture, users need to open their hands and place palm regions in front of the cameras. Also, the palm plane needs to be approximately flat and orthogonal to the optical axis of cameras. Minor in-plane rotation is allowed. The distance between the hand and device should be in a fixed range (35–50 cm) to ensure the clarity of the palmprint images. In [3], a novel touchless device with a single camera is proposed. The principle of device design is similar to [2]. During the input process, the user places his/her hand in front of the camera without touching the device, and there are no strict constraints on its pose and location. The main difference is that the paddles are placed around the camera to reduce the effect of illumination changes. By these measures, the acquisition process becomes flexible and efficient. [6] presents a touchless palmprint and palm vein recognition system. The structure of the device is similar to that in [3], which mainly contains two parallel mounted cameras with visible light and IR light. The flexibility of this touchless device is further improved. Users are allowed to position their hands freely above the sensor, and they can move their hands during the acquisition process. The acquisition program will give feedback to the user that he/she is placing his/her hand correctly inside the working volume. In this way, the device can capture high-quality palmprint and palm vein images at the same time. In [7], the palmprint, palm vein, and dorsal vein images are simultaneously captured with a touchless acquisition device. In the capturing process, the users are asked to put their hands into the device with five fingers separated. The time cost is less than 1 s. The multimodal images can be fused in the algorithm to boost the identification performance.
With the widespread application of digital cameras and smartphones, more and more portable biometric devices appear to us. To investigate the problem of palmprint recognition across different portable devices and build the available dataset, [8] uses one digital camera and two smartphones to acquire palmprints in a free manner.
As is discussed above, the main parts of palmprint acquisition devices are cameras and light sources. So, the problems we need to consider when designing new devices are as follows:
The resolution of the imaging sensor
The focal length of the lens
The distance range of the palm
The sharpness range of the final palmprint image
The light source intensity
The signal-to-noise ratio of the palmprint image
Many previous works have studied the light sources [15, 16, 17]. Generally, the basic goal is avoiding overexposure and underexposure. Image noise increases under low illumination conditions. Although many new deep learning-based denoising techniques are proposed [18], the most effective solution for palmprint imaging is developing active light sources to provide suitable illumination conditions. In this work, we only focus on the first four problems. We developed three palm image capture devices to test the performance of different hardware frameworks (as is shown in Figure 2). We denote them as
Different palmprint acquisition devices and the palm images generated by them. (a) The touch-based device with a 500 M pixel imaging sensor and a long imaging distance. (b) The touch-based device with a 120 M pixel imaging sensor and a very short imaging distance. (c) The multicamera touchless device with 120 M and 30 M pixel imaging sensors and a long imaging distance. (d) The palm image captured by (a) and the corresponding enlarged local regions. (e) The palm image captured by (b) and the corresponding enlarged local regions. (f) The palm images captured by (c) and the corresponding enlarged local regions.
The imaging model is shown in Figure 3. Let
Imaging model and related notations.
where
in which
where
Hence,
where
where
where N is the image number of the dataset and
Images captured by different lenses. (a) The imaging device and different kinds of lenses. (b) An image captured by long-focus lens. (c) An image captured by standard lens. (d) An image captured by ultrawide-angle lens.
Lens | |||||||||
---|---|---|---|---|---|---|---|---|---|
Long-focus | 3507.05 | 3497.24 | 10.4° | 7.9° | −0.37 | −1.36 | — | −0.0018 | −0.0000 |
Standard | 706.96 | 707.29 | 48.7° | 37.5° | 0.13 | −0.51 | — | 0.0055 | −0.0001 |
Wide-angle | 435.57 | 436.10 | 72.6° | 57.7° | −0.41 | 0.14 | — | 0.0014 | 0.0006 |
Ultrawide | 217.19 | 217.99 | 111.7° | 95.5° | 0.05 | −0.07 | 0.0105 | −0.0002 | −0.0018 |
The calibrated parameters of different camera lenses.
Images obtained at different distances (PPI) using different distortion models.
Palm region size | ×960 | ×840 | ×720 | ×600 | ×480 | ×360 | ×240 | ×180 | ×120 | ×60 |
---|---|---|---|---|---|---|---|---|---|---|
304.8 | 266.7 | 228.6 | 190.5 | 152.4 | 114.3 | 76.2 | 57.2 | 38.1 | 19.1 | |
524.8 | 459.2 | 393.6 | 328.0 | 262.4 | 196.8 | 131.2 | 98.4 | 65.6 | 32.8 | |
166.6 | 145.8 | 125.0 | 104.1 | 83.3 | 62.5 | 41.7 | 31.2 | 20.8 | 10.4 |
Palm region size, palm width, and corresponding
Long-focus | Standard | Wide-angle | Ultrawide | |||||
---|---|---|---|---|---|---|---|---|
EER (%) | EER (%) | EER (%) | EER (%) | |||||
524.8 | 1.445 | 29.0 | 1.539 | 28.6 | 1.508 | 28.1 | 1.634 | 28.4 |
459.2 | 1.477 | 26.5 | 1.634 | 26.3 | 1.571 | 25.9 | 1.602 | 26.1 |
393.6 | 1.445 | 26.1 | 1.619 | 25.9 | 1.553 | 25.5 | 1.634 | 25.8 |
328.0 | 1.414 | 25.4 | 1.571 | 25.3 | 1.550 | 25.1 | 1.631 | 25.3 |
262.4 | 1.414 | 23.7 | 1.602 | 23.6 | 1.508 | 23.4 | 1.539 | 23.6 |
196.8 | 1.477 | 23.9 | 1.571 | 23.5 | 1.539 | 23.1 | 1.602 | 23.2 |
131.2 | 1.508 | 20.2 | 1.783 | 20.0 | 1.634 | 19.7 | 1.627 | 19.8 |
98.4 | 1.571 | 18.4 | 1.759 | 18.3 | 1.728 | 18.1 | 1.728 | 18.2 |
65.6 | 2.177 | 14.8 | 2.136 | 14.7 | 2.325 | 14.6 | 2.262 | 14.7 |
32.8 | 6.346 | 9.9 | 6.313 | 9.8 | 6.274 | 9.8 | 6.535 | 9.8 |
The EERs obtained from different palm width using different lens models.
The relationship between recognition performance, image sharpness, and palm width (in units of pixel).
In the above subsection, based on the imaging model and the capture device, we studied the relationship between palm distance, PPI, and EER. However, the hardware and the parameters of the imaging model are not always available in practice. Besides FOV, depth of focus (DOF) should be considered, since defocus-blur also will affect the final accuracy. DOF is highly related to specific applications. Our previous work [23] shows that the accuracy of palmprint recognition has a relationship with the image sharpness. Here, what we want to know is in which sharpness range the palmprint recognition accuracy is acceptable.
In this section, we try to analyze the palmprint image sharpness based on the Gaussian scale space [24]. The transform function is defined as
where
The palmprint Gaussian scale space.
Scale contributions for key point matching: (a) obtained from COEP, (b) obtained from IITD, (c) obtained from KTU, (d) obtained from GPDS.
In order to analyze the recognition performance variations, we utilize the Gaussian image pyramid to generate palmprint images at different scales. For a given dataset, all the ROI images in it are filtered with Gaussian filter banks, and then 20 scaled datasets are generated. The
where
The curves of
The work reported in [27] shows that there exist a relationship between the recognition performance and the image sharpness. In their work, a sharpness adjustment technique is developed to improve the system EER. Different sharpness induces are tested, and EAV performs better. But only one touch-based palmprint database is tested in their study. In order to ensure the idea is applicable on different databases, devices, and algorithms, we utilize CompCode [28], OLOF [29], and RLOC [30] to further test the recognition accuracy variations on those generated datasets. In this experiment, different databases are used including GPDS [31], IITD [32], KTU [33], and TJU [34]. Figure 10 shows the curves of EER and corresponding
The curves of EER and
When designing a touchless palmprint recognition system, FOV and DOF are two key problems of palmprint imaging. FOV is related to image PPI, and DOF is related to image blur. Figure 11 shows the main idea and framework of our system. In this chapter, we first studied the required image PPI for palmprint identification. Based on it, the minimum and maximum palm distances are determined in the FOV. It also provides a reference for image sensor resolution selection. Then, image blur is taken into consideration; different datasets are generated by Gaussian scale space function. The EER variation curves are obtained by different features on different databases. During the image collection process, when the palm moves out of the DOF, the sharpness of the captured image changes, so
The framework of this chapter.
Based on the findings of this research, when designing new systems, the palm width in the captured image should be larger than 300 pixels; it at least should not smaller than 130 pixels. After the system is deployed, when the user is putting his/her hand, the
This work is supported in part by the NSFC under grant 61332011, in part by the Shenzhen Fundamental Research under grants JCYJ20180306172023949 and JCYJ20170412170438636, in part by the Shenzhen Institute of Artificial Intelligence and Robotics for Society.
"Open access contributes to scientific excellence and integrity. It opens up research results to wider analysis. It allows research results to be reused for new discoveries. And it enables the multi-disciplinary research that is needed to solve global 21st century problems. Open access connects science with society. It allows the public to engage with research. To go behind the headlines. And look at the scientific evidence. And it enables policy makers to draw on innovative solutions to societal challenges".
\n\nCarlos Moedas, the European Commissioner for Research Science and Innovation at the STM Annual Frankfurt Conference, October 2016.
",metaTitle:"About Open Access",metaDescription:"Open access contributes to scientific excellence and integrity. It opens up research results to wider analysis. It allows research results to be reused for new discoveries. And it enables the multi-disciplinary research that is needed to solve global 21st century problems. Open access connects science with society. It allows the public to engage with research. To go behind the headlines. And look at the scientific evidence. And it enables policy makers to draw on innovative solutions to societal challenges.\n\nCarlos Moedas, the European Commissioner for Research Science and Innovation at the STM Annual Frankfurt Conference, October 2016.",metaKeywords:null,canonicalURL:"about-open-access",contentRaw:'[{"type":"htmlEditorComponent","content":"The Open Access publishing movement started in the early 2000s when academic leaders from around the world participated in the formation of the Budapest Initiative. They developed recommendations for an Open Access publishing process, “which has worked for the past decade to provide the public with unrestricted, free access to scholarly research—much of which is publicly funded. Making the research publicly available to everyone—free of charge and without most copyright and licensing restrictions—will accelerate scientific research efforts and allow authors to reach a larger number of readers” (reference: http://www.budapestopenaccessinitiative.org)
\\n\\nIntechOpen’s co-founders, both scientists themselves, created the company while undertaking research in robotics at Vienna University. Their goal was to spread research freely “for scientists, by scientists’ to the rest of the world via the Open Access publishing model. The company soon became a signatory of the Budapest Initiative, which currently has more than 1000 supporting organizations worldwide, ranging from universities to funders.
\\n\\nAt IntechOpen today, we are still as committed to working with organizations and people who care about scientific discovery, to putting the academic needs of the scientific community first, and to providing an Open Access environment where scientists can maximize their contribution to scientific advancement. By opening up access to the world’s scientific research articles and book chapters, we aim to facilitate greater opportunity for collaboration, scientific discovery and progress. We subscribe wholeheartedly to the Open Access definition:
\\n\\n“By “open access” to [peer-reviewed research literature], we mean its free availability on the public internet, permitting any users to read, download, copy, distribute, print, search, or link to the full texts of these articles, crawl them for indexing, pass them as data to software, or use them for any other lawful purpose, without financial, legal, or technical barriers other than those inseparable from gaining access to the internet itself. The only constraint on reproduction and distribution, and the only role for copyright in this domain, should be to give authors control over the integrity of their work and the right to be properly acknowledged and cited” (reference: http://www.budapestopenaccessinitiative.org)
\\n\\nOAI-PMH
\\n\\nAs a firm believer in the wider dissemination of knowledge, IntechOpen supports the Open Access Initiative Protocol for Metadata Harvesting (OAI-PMH Version 2.0). Read more
\\n\\nLicense
\\n\\nBook chapters published in edited volumes are distributed under the Creative Commons Attribution 3.0 Unported License (CC BY 3.0). IntechOpen upholds a very flexible Copyright Policy. There is no copyright transfer to the publisher and Authors retain exclusive copyright to their work. All Monographs/Compacts are distributed under the Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). Read more
\\n\\nPeer Review Policies
\\n\\nAll scientific works are Peer Reviewed prior to publishing. Read more
\\n\\nOA Publishing Fees
\\n\\nThe Open Access publishing model employed by IntechOpen eliminates subscription charges and pay-per-view fees, enabling readers to access research at no cost. In order to sustain operations and keep our publications freely accessible we levy an Open Access Publishing Fee for manuscripts, which helps us cover the costs of editorial work and the production of books. Read more
\\n\\nDigital Archiving Policy
\\n\\nIntechOpen is committed to ensuring the long-term preservation and the availability of all scholarly research we publish. We employ a variety of means to enable us to deliver on our commitments to the scientific community. Apart from preservation by the Croatian National Library (for publications prior to April 18, 2018) and the British Library (for publications after April 18, 2018), our entire catalogue is preserved in the CLOCKSS archive.
\\n\\nOpen Science is transparent and accessible knowledge that is shared and developed through collaborative networks.
\\n\\nOpen Science is about increased rigour, accountability, and reproducibility for research. It is based on the principles of inclusion, fairness, equity, and sharing, and ultimately seeks to change the way research is done, who is involved and how it is valued. It aims to make research more open to participation, review/refutation, improvement and (re)use for the world to benefit.
\\n\\nOpen Science refers to doing traditional science with more transparency involved at various stages, for example by openly sharing code and data. It implies a growing set of practices - within different disciplines - aiming at:
\\n\\nWe aim at improving the quality and availability of scholarly communication by promoting and practicing:
\\n\\n\\n"}]'},components:[{type:"htmlEditorComponent",content:'
The Open Access publishing movement started in the early 2000s when academic leaders from around the world participated in the formation of the Budapest Initiative. They developed recommendations for an Open Access publishing process, “which has worked for the past decade to provide the public with unrestricted, free access to scholarly research—much of which is publicly funded. Making the research publicly available to everyone—free of charge and without most copyright and licensing restrictions—will accelerate scientific research efforts and allow authors to reach a larger number of readers” (reference: http://www.budapestopenaccessinitiative.org)
\n\nIntechOpen’s co-founders, both scientists themselves, created the company while undertaking research in robotics at Vienna University. Their goal was to spread research freely “for scientists, by scientists’ to the rest of the world via the Open Access publishing model. The company soon became a signatory of the Budapest Initiative, which currently has more than 1000 supporting organizations worldwide, ranging from universities to funders.
\n\nAt IntechOpen today, we are still as committed to working with organizations and people who care about scientific discovery, to putting the academic needs of the scientific community first, and to providing an Open Access environment where scientists can maximize their contribution to scientific advancement. By opening up access to the world’s scientific research articles and book chapters, we aim to facilitate greater opportunity for collaboration, scientific discovery and progress. We subscribe wholeheartedly to the Open Access definition:
\n\n“By “open access” to [peer-reviewed research literature], we mean its free availability on the public internet, permitting any users to read, download, copy, distribute, print, search, or link to the full texts of these articles, crawl them for indexing, pass them as data to software, or use them for any other lawful purpose, without financial, legal, or technical barriers other than those inseparable from gaining access to the internet itself. The only constraint on reproduction and distribution, and the only role for copyright in this domain, should be to give authors control over the integrity of their work and the right to be properly acknowledged and cited” (reference: http://www.budapestopenaccessinitiative.org)
\n\nOAI-PMH
\n\nAs a firm believer in the wider dissemination of knowledge, IntechOpen supports the Open Access Initiative Protocol for Metadata Harvesting (OAI-PMH Version 2.0). Read more
\n\nLicense
\n\nBook chapters published in edited volumes are distributed under the Creative Commons Attribution 3.0 Unported License (CC BY 3.0). IntechOpen upholds a very flexible Copyright Policy. There is no copyright transfer to the publisher and Authors retain exclusive copyright to their work. All Monographs/Compacts are distributed under the Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). Read more
\n\nPeer Review Policies
\n\nAll scientific works are Peer Reviewed prior to publishing. Read more
\n\nOA Publishing Fees
\n\nThe Open Access publishing model employed by IntechOpen eliminates subscription charges and pay-per-view fees, enabling readers to access research at no cost. In order to sustain operations and keep our publications freely accessible we levy an Open Access Publishing Fee for manuscripts, which helps us cover the costs of editorial work and the production of books. Read more
\n\nDigital Archiving Policy
\n\nIntechOpen is committed to ensuring the long-term preservation and the availability of all scholarly research we publish. We employ a variety of means to enable us to deliver on our commitments to the scientific community. Apart from preservation by the Croatian National Library (for publications prior to April 18, 2018) and the British Library (for publications after April 18, 2018), our entire catalogue is preserved in the CLOCKSS archive.
\n\nOpen Science is transparent and accessible knowledge that is shared and developed through collaborative networks.
\n\nOpen Science is about increased rigour, accountability, and reproducibility for research. It is based on the principles of inclusion, fairness, equity, and sharing, and ultimately seeks to change the way research is done, who is involved and how it is valued. It aims to make research more open to participation, review/refutation, improvement and (re)use for the world to benefit.
\n\nOpen Science refers to doing traditional science with more transparency involved at various stages, for example by openly sharing code and data. It implies a growing set of practices - within different disciplines - aiming at:
\n\nWe aim at improving the quality and availability of scholarly communication by promoting and practicing:
\n\n\n'}]},successStories:{items:[]},authorsAndEditors:{filterParams:{sort:"featured,name"},profiles:[],filtersByRegion:[],offset:0,limit:12,total:null},chapterEmbeded:{data:{}},editorApplication:{success:null,errors:{}},ofsBooks:{filterParams:{hasNoEditors:"0",sort:"-dateEndThirdStepPublish",src:"N-T-0-T1-NW"},books:[{type:"book",id:"9985",title:"Geostatistics",subtitle:null,isOpenForSubmission:!0,hash:"423cb3896195a618c4acb493ce4fd23d",slug:null,bookSignature:"Prof. Jeffrey M. Yarus, Dr. Marko Maucec, Dr. Timothy C. Coburn and Associate Prof. Michael Pyrcz",coverURL:"https://cdn.intechopen.com/books/images_new/9985.jpg",editedByType:null,editors:[{id:"78011",title:"Prof.",name:"Jeffrey M.",surname:"Yarus",slug:"jeffrey-m.-yarus",fullName:"Jeffrey M. Yarus"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"11513",title:"Gas Sensors",subtitle:null,isOpenForSubmission:!0,hash:"8eeb7ab232fa8d5c723b61e0da251857",slug:null,bookSignature:"Dr. Soumen Dhara and Dr. Gorachand Dutta",coverURL:"https://cdn.intechopen.com/books/images_new/11513.jpg",editedByType:null,editors:[{id:"196334",title:"Dr.",name:"Soumen",surname:"Dhara",slug:"soumen-dhara",fullName:"Soumen Dhara"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"12050",title:"Advanced Biodiesel - Technological Advances, Challenges, and Sustainability Considerations",subtitle:null,isOpenForSubmission:!0,hash:"bb86ab5c5ca0dab95f01941eb350f920",slug:null,bookSignature:"Dr. IMR Fattah",coverURL:"https://cdn.intechopen.com/books/images_new/12050.jpg",editedByType:null,editors:[{id:"463663",title:"Dr.",name:"IMR",surname:"Fattah",slug:"imr-fattah",fullName:"IMR Fattah"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"12059",title:"Hydraulic Structures - Impact on River Flow and Sediment Transport-Dimensioning",subtitle:null,isOpenForSubmission:!0,hash:"8e41aab8223c29ce69c00e8c8f6f560d",slug:null,bookSignature:"Prof. Vlassios Hrissanthou",coverURL:"https://cdn.intechopen.com/books/images_new/12059.jpg",editedByType:null,editors:[{id:"37707",title:"Prof.",name:"Vlassios",surname:"Hrissanthou",slug:"vlassios-hrissanthou",fullName:"Vlassios Hrissanthou"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"12061",title:"Masonry for Sustainable Construction",subtitle:null,isOpenForSubmission:!0,hash:"85ef86d046d15e7d4b1988f1ec5dd750",slug:null,bookSignature:"Prof. Amjad Almusaed and Prof. Asaad Almssad",coverURL:"https://cdn.intechopen.com/books/images_new/12061.jpg",editedByType:null,editors:[{id:"446856",title:"Prof.",name:"Amjad",surname:"Almusaed",slug:"amjad-almusaed",fullName:"Amjad Almusaed"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"11817",title:"Next Generation Fiber-Reinforced Composites - New Insights",subtitle:null,isOpenForSubmission:!0,hash:"bdff63f3c5e98fc95d76217516cb1420",slug:null,bookSignature:"Dr. Longbiao Li",coverURL:"https://cdn.intechopen.com/books/images_new/11817.jpg",editedByType:null,editors:[{id:"260011",title:"Dr.",name:"Longbiao",surname:"Li",slug:"longbiao-li",fullName:"Longbiao Li"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"12078",title:"Schiff Base in Organic, Inorganic and Physical Chemistry",subtitle:null,isOpenForSubmission:!0,hash:"ce51efbe2cae97ca3199350ef6c498ec",slug:null,bookSignature:"Dr. Takashiro Akitsu",coverURL:"https://cdn.intechopen.com/books/images_new/12078.jpg",editedByType:null,editors:[{id:"147861",title:"Dr.",name:"Takashiro",surname:"Akitsu",slug:"takashiro-akitsu",fullName:"Takashiro Akitsu"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"11556",title:"Numerical Simulation",subtitle:null,isOpenForSubmission:!0,hash:"0a68fbeb303684344bda285aa06769af",slug:null,bookSignature:"Dr. Ali Soofastaei",coverURL:"https://cdn.intechopen.com/books/images_new/11556.jpg",editedByType:null,editors:[{id:"257455",title:"Dr.",name:"Ali",surname:"Soofastaei",slug:"ali-soofastaei",fullName:"Ali Soofastaei"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"12107",title:"Contemporary Topics in Patient Safety - Volume 2",subtitle:null,isOpenForSubmission:!0,hash:"3fe674b93710773f0db746ca96d6e048",slug:null,bookSignature:"Dr. Philip Salen and Dr. Stanislaw P. Stawicki",coverURL:"https://cdn.intechopen.com/books/images_new/12107.jpg",editedByType:null,editors:[{id:"217603",title:"Dr.",name:"Philip",surname:"Salen",slug:"philip-salen",fullName:"Philip Salen"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"11784",title:"Bryophytes - The State of Knowledge in a World Under Climate Change",subtitle:null,isOpenForSubmission:!0,hash:"80743b2add35e11b09c10e6895a45831",slug:null,bookSignature:"Prof. Jair Putzke",coverURL:"https://cdn.intechopen.com/books/images_new/11784.jpg",editedByType:null,editors:[{id:"324930",title:"Prof.",name:"Jair",surname:"Putzke",slug:"jair-putzke",fullName:"Jair Putzke"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"11903",title:"Covalent Organic Frameworks",subtitle:null,isOpenForSubmission:!0,hash:"8125f3f415f5d2fa9583abde0143602d",slug:null,bookSignature:"Prof. Yanan Gao and Dr. Fei Lu",coverURL:"https://cdn.intechopen.com/books/images_new/11903.jpg",editedByType:null,editors:[{id:"171387",title:"Prof.",name:"Yanan",surname:"Gao",slug:"yanan-gao",fullName:"Yanan Gao"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"11992",title:"New Advances in Carbon Fibers",subtitle:null,isOpenForSubmission:!0,hash:"f4c2d09100983c6404dba2981b93b0cb",slug:null,bookSignature:"Prof. Guanming Yuan",coverURL:"https://cdn.intechopen.com/books/images_new/11992.jpg",editedByType:null,editors:[{id:"308403",title:"Prof.",name:"Guanming",surname:"Yuan",slug:"guanming-yuan",fullName:"Guanming Yuan"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}}],filtersByTopic:[{group:"topic",caption:"Agricultural and Biological Sciences",value:5,count:43},{group:"topic",caption:"Biochemistry, Genetics and Molecular Biology",value:6,count:11},{group:"topic",caption:"Business, Management and Economics",value:7,count:6},{group:"topic",caption:"Chemistry",value:8,count:23},{group:"topic",caption:"Computer and Information Science",value:9,count:21},{group:"topic",caption:"Earth and Planetary Sciences",value:10,count:17},{group:"topic",caption:"Engineering",value:11,count:62},{group:"topic",caption:"Environmental Sciences",value:12,count:9},{group:"topic",caption:"Immunology and Microbiology",value:13,count:10},{group:"topic",caption:"Materials Science",value:14,count:29},{group:"topic",caption:"Mathematics",value:15,count:10},{group:"topic",caption:"Medicine",value:16,count:123},{group:"topic",caption:"Nanotechnology and Nanomaterials",value:17,count:9},{group:"topic",caption:"Neuroscience",value:18,count:3},{group:"topic",caption:"Pharmacology, Toxicology and Pharmaceutical Science",value:19,count:7},{group:"topic",caption:"Physics",value:20,count:12},{group:"topic",caption:"Psychology",value:21,count:10},{group:"topic",caption:"Robotics",value:22,count:4},{group:"topic",caption:"Social Sciences",value:23,count:8},{group:"topic",caption:"Veterinary Medicine and Science",value:25,count:4}],offset:12,limit:12,total:423},popularBooks:{featuredBooks:[{type:"book",id:"10584",title:"Engineered Wood Products for Construction",subtitle:null,isOpenForSubmission:!1,hash:"421757c56a3735986055250821275a51",slug:"engineered-wood-products-for-construction",bookSignature:"Meng Gong",coverURL:"https://cdn.intechopen.com/books/images_new/10584.jpg",editors:[{id:"274242",title:"Dr.",name:"Meng",middleName:null,surname:"Gong",slug:"meng-gong",fullName:"Meng Gong"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10222",title:"Demyelination Disorders",subtitle:null,isOpenForSubmission:!1,hash:"b6c26ceccacdde70c41c587361bd5558",slug:"demyelination-disorders",bookSignature:"Stavros J. Baloyannis, Fabian H. Rossi and Welwin Liu",coverURL:"https://cdn.intechopen.com/books/images_new/10222.jpg",editors:[{id:"156098",title:"Emeritus Prof.",name:"Stavros J.",middleName:"J.",surname:"Baloyannis",slug:"stavros-j.-baloyannis",fullName:"Stavros J. Baloyannis"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9544",title:"Global Trade in the Emerging Business Environment",subtitle:null,isOpenForSubmission:!1,hash:"fb8cb09b9599246add78d508a98273d5",slug:"global-trade-in-the-emerging-business-environment",bookSignature:"Muhammad Mohiuddin, Jingbin Wang , Md. Samim Al Azad and Selim Ahmed",coverURL:"https://cdn.intechopen.com/books/images_new/9544.jpg",editors:[{id:"418514",title:"Dr.",name:"Muhammad",middleName:null,surname:"Mohiuddin",slug:"muhammad-mohiuddin",fullName:"Muhammad Mohiuddin"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10979",title:"Parenting",subtitle:"Challenges of Child Rearing in a Changing Society",isOpenForSubmission:!1,hash:"6f345ebcf4fd61e73643c69063a12c7b",slug:"parenting-challenges-of-child-rearing-in-a-changing-society",bookSignature:"Sayyed Ali Samadi",coverURL:"https://cdn.intechopen.com/books/images_new/10979.jpg",editors:[{id:"52145",title:"Dr.",name:"Sayyed Ali",middleName:null,surname:"Samadi",slug:"sayyed-ali-samadi",fullName:"Sayyed Ali Samadi"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9808",title:"Contemporary Topics in Patient Safety",subtitle:"Volume 1",isOpenForSubmission:!1,hash:"fb6371607c2c6c02c6a2af8892765aba",slug:"contemporary-topics-in-patient-safety-volume-1",bookSignature:"Stanislaw P. Stawicki and Michael S. Firstenberg",coverURL:"https://cdn.intechopen.com/books/images_new/9808.jpg",editors:[{id:"181694",title:"Dr.",name:"Stanislaw P.",middleName:null,surname:"Stawicki",slug:"stanislaw-p.-stawicki",fullName:"Stanislaw P. Stawicki"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10681",title:"Biodegradation Technology of Organic and Inorganic Pollutants",subtitle:null,isOpenForSubmission:!1,hash:"9a6e10e02788092872fd249436898e97",slug:"biodegradation-technology-of-organic-and-inorganic-pollutants",bookSignature:"Kassio Ferreira Mendes, Rodrigo Nogueira de Sousa and Kamila Cabral Mielke",coverURL:"https://cdn.intechopen.com/books/images_new/10681.jpg",editors:[{id:"197720",title:"Ph.D.",name:"Kassio",middleName:null,surname:"Ferreira Mendes",slug:"kassio-ferreira-mendes",fullName:"Kassio Ferreira Mendes"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10764",title:"Antenna Systems",subtitle:null,isOpenForSubmission:!1,hash:"2fbf1c7a5d92723f08198fc9b526a8ad",slug:"antenna-systems",bookSignature:"Hussain Al-Rizzo and Said Abushamleh",coverURL:"https://cdn.intechopen.com/books/images_new/10764.jpg",editors:[{id:"153384",title:"Prof.",name:"Hussain",middleName:null,surname:"Al-Rizzo",slug:"hussain-al-rizzo",fullName:"Hussain Al-Rizzo"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10668",title:"Sustainability of Concrete With Synthetic and Recycled Aggregates",subtitle:null,isOpenForSubmission:!1,hash:"55856c6a8bc3a5b21dae5a1af09a56b6",slug:"sustainability-of-concrete-with-synthetic-and-recycled-aggregates",bookSignature:"Hosam M. Saleh",coverURL:"https://cdn.intechopen.com/books/images_new/10668.jpg",editors:[{id:"144691",title:"Prof.",name:"Hosam",middleName:null,surname:"Saleh",slug:"hosam-saleh",fullName:"Hosam Saleh"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10803",title:"Reactive Oxygen Species",subtitle:null,isOpenForSubmission:!1,hash:"176adcf090fdd1f93cb8ce3146e79ca1",slug:"reactive-oxygen-species",bookSignature:"Rizwan Ahmad",coverURL:"https://cdn.intechopen.com/books/images_new/10803.jpg",editors:[{id:"40482",title:null,name:"Rizwan",middleName:null,surname:"Ahmad",slug:"rizwan-ahmad",fullName:"Rizwan Ahmad"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9032",title:"Corporate Social Responsibility",subtitle:null,isOpenForSubmission:!1,hash:"f609bf3251d7cc7bae0099a4374adfc3",slug:"corporate-social-responsibility",bookSignature:"Beatrice Orlando",coverURL:"https://cdn.intechopen.com/books/images_new/9032.jpg",editors:[{id:"232969",title:"Prof.",name:"Beatrice",middleName:null,surname:"Orlando",slug:"beatrice-orlando",fullName:"Beatrice Orlando"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10351",title:"Enhanced Liposuction",subtitle:"New Perspectives and Techniques",isOpenForSubmission:!1,hash:"f08ed6de16da357614586c5b58ed4dfa",slug:"enhanced-liposuction-new-perspectives-and-techniques",bookSignature:"Diane Irvine Duncan",coverURL:"https://cdn.intechopen.com/books/images_new/10351.jpg",editors:[{id:"279869",title:"Dr.",name:"Diane Irvine",middleName:null,surname:"Duncan",slug:"diane-irvine-duncan",fullName:"Diane Irvine Duncan"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10779",title:"21st Century Nanostructured Materials",subtitle:"Physics, Chemistry, Classification, and Emerging Applications in Industry, Biomedicine, and Agriculture",isOpenForSubmission:!1,hash:"72c67f97f9bef68200df115b5fd79884",slug:"21st-century-nanostructured-materials-physics-chemistry-classification-and-emerging-applications-in-industry-biomedicine-and-agriculture",bookSignature:"Phuong V. Pham",coverURL:"https://cdn.intechopen.com/books/images_new/10779.jpg",editors:[{id:"236073",title:"Dr.",name:"Phuong",middleName:"Viet",surname:"Pham",slug:"phuong-pham",fullName:"Phuong Pham"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}}],offset:12,limit:12,total:4389},hotBookTopics:{hotBooks:[],offset:0,limit:12,total:null},publish:{},publishingProposal:{success:null,errors:{}},books:{featuredBooks:[{type:"book",id:"10584",title:"Engineered Wood Products for Construction",subtitle:null,isOpenForSubmission:!1,hash:"421757c56a3735986055250821275a51",slug:"engineered-wood-products-for-construction",bookSignature:"Meng Gong",coverURL:"https://cdn.intechopen.com/books/images_new/10584.jpg",publishedDate:"April 28th 2022",numberOfDownloads:3665,editors:[{id:"274242",title:"Dr.",name:"Meng",middleName:null,surname:"Gong",slug:"meng-gong",fullName:"Meng Gong"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10222",title:"Demyelination Disorders",subtitle:null,isOpenForSubmission:!1,hash:"b6c26ceccacdde70c41c587361bd5558",slug:"demyelination-disorders",bookSignature:"Stavros J. Baloyannis, Fabian H. Rossi and Welwin Liu",coverURL:"https://cdn.intechopen.com/books/images_new/10222.jpg",publishedDate:"May 4th 2022",numberOfDownloads:1713,editors:[{id:"156098",title:"Emeritus Prof.",name:"Stavros J.",middleName:"J.",surname:"Baloyannis",slug:"stavros-j.-baloyannis",fullName:"Stavros J. Baloyannis"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9544",title:"Global Trade in the Emerging Business Environment",subtitle:null,isOpenForSubmission:!1,hash:"fb8cb09b9599246add78d508a98273d5",slug:"global-trade-in-the-emerging-business-environment",bookSignature:"Muhammad Mohiuddin, Jingbin Wang , Md. Samim Al Azad and Selim Ahmed",coverURL:"https://cdn.intechopen.com/books/images_new/9544.jpg",publishedDate:"April 28th 2022",numberOfDownloads:2481,editors:[{id:"418514",title:"Dr.",name:"Muhammad",middleName:null,surname:"Mohiuddin",slug:"muhammad-mohiuddin",fullName:"Muhammad Mohiuddin"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10979",title:"Parenting",subtitle:"Challenges of Child Rearing in a Changing Society",isOpenForSubmission:!1,hash:"6f345ebcf4fd61e73643c69063a12c7b",slug:"parenting-challenges-of-child-rearing-in-a-changing-society",bookSignature:"Sayyed Ali Samadi",coverURL:"https://cdn.intechopen.com/books/images_new/10979.jpg",publishedDate:"May 4th 2022",numberOfDownloads:1107,editors:[{id:"52145",title:"Dr.",name:"Sayyed Ali",middleName:null,surname:"Samadi",slug:"sayyed-ali-samadi",fullName:"Sayyed Ali Samadi"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9808",title:"Contemporary Topics in Patient Safety",subtitle:"Volume 1",isOpenForSubmission:!1,hash:"fb6371607c2c6c02c6a2af8892765aba",slug:"contemporary-topics-in-patient-safety-volume-1",bookSignature:"Stanislaw P. Stawicki and Michael S. Firstenberg",coverURL:"https://cdn.intechopen.com/books/images_new/9808.jpg",publishedDate:"April 20th 2022",numberOfDownloads:3307,editors:[{id:"181694",title:"Dr.",name:"Stanislaw P.",middleName:null,surname:"Stawicki",slug:"stanislaw-p.-stawicki",fullName:"Stanislaw P. Stawicki"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10681",title:"Biodegradation Technology of Organic and Inorganic Pollutants",subtitle:null,isOpenForSubmission:!1,hash:"9a6e10e02788092872fd249436898e97",slug:"biodegradation-technology-of-organic-and-inorganic-pollutants",bookSignature:"Kassio Ferreira Mendes, Rodrigo Nogueira de Sousa and Kamila Cabral Mielke",coverURL:"https://cdn.intechopen.com/books/images_new/10681.jpg",publishedDate:"April 20th 2022",numberOfDownloads:3266,editors:[{id:"197720",title:"Ph.D.",name:"Kassio",middleName:null,surname:"Ferreira Mendes",slug:"kassio-ferreira-mendes",fullName:"Kassio Ferreira Mendes"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10764",title:"Antenna Systems",subtitle:null,isOpenForSubmission:!1,hash:"2fbf1c7a5d92723f08198fc9b526a8ad",slug:"antenna-systems",bookSignature:"Hussain Al-Rizzo and Said Abushamleh",coverURL:"https://cdn.intechopen.com/books/images_new/10764.jpg",publishedDate:"April 28th 2022",numberOfDownloads:1868,editors:[{id:"153384",title:"Prof.",name:"Hussain",middleName:null,surname:"Al-Rizzo",slug:"hussain-al-rizzo",fullName:"Hussain Al-Rizzo"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10668",title:"Sustainability of Concrete With Synthetic and Recycled Aggregates",subtitle:null,isOpenForSubmission:!1,hash:"55856c6a8bc3a5b21dae5a1af09a56b6",slug:"sustainability-of-concrete-with-synthetic-and-recycled-aggregates",bookSignature:"Hosam M. Saleh",coverURL:"https://cdn.intechopen.com/books/images_new/10668.jpg",publishedDate:"May 4th 2022",numberOfDownloads:856,editors:[{id:"144691",title:"Prof.",name:"Hosam",middleName:null,surname:"Saleh",slug:"hosam-saleh",fullName:"Hosam Saleh"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10803",title:"Reactive Oxygen Species",subtitle:null,isOpenForSubmission:!1,hash:"176adcf090fdd1f93cb8ce3146e79ca1",slug:"reactive-oxygen-species",bookSignature:"Rizwan Ahmad",coverURL:"https://cdn.intechopen.com/books/images_new/10803.jpg",publishedDate:"April 28th 2022",numberOfDownloads:1704,editors:[{id:"40482",title:null,name:"Rizwan",middleName:null,surname:"Ahmad",slug:"rizwan-ahmad",fullName:"Rizwan Ahmad"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9032",title:"Corporate Social Responsibility",subtitle:null,isOpenForSubmission:!1,hash:"f609bf3251d7cc7bae0099a4374adfc3",slug:"corporate-social-responsibility",bookSignature:"Beatrice Orlando",coverURL:"https://cdn.intechopen.com/books/images_new/9032.jpg",publishedDate:"March 16th 2022",numberOfDownloads:7489,editors:[{id:"232969",title:"Prof.",name:"Beatrice",middleName:null,surname:"Orlando",slug:"beatrice-orlando",fullName:"Beatrice Orlando"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}}],latestBooks:[{type:"book",id:"10251",title:"Plankton Communities",subtitle:null,isOpenForSubmission:!1,hash:"e11e441ca2d2d5f631b1b4704505cfb6",slug:"plankton-communities",bookSignature:"Leonel Pereira and Ana Marta Gonçalves",coverURL:"https://cdn.intechopen.com/books/images_new/10251.jpg",editedByType:"Edited by",publishedDate:"May 18th 2022",editors:[{id:"279788",title:"Dr.",name:"Leonel",middleName:null,surname:"Pereira",slug:"leonel-pereira",fullName:"Leonel Pereira"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10830",title:"Animal Feed Science and Nutrition",subtitle:"Production, Health and Environment",isOpenForSubmission:!1,hash:"79944fc8fbbaa329aed6fde388154832",slug:"animal-feed-science-and-nutrition-production-health-and-environment",bookSignature:"Amlan Kumar Patra",coverURL:"https://cdn.intechopen.com/books/images_new/10830.jpg",editedByType:"Edited by",publishedDate:"May 18th 2022",editors:[{id:"310962",title:"Dr.",name:"Amlan",middleName:"Kumar",surname:"Patra",slug:"amlan-patra",fullName:"Amlan Patra"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10853",title:"Recent Advances in Polynomials",subtitle:null,isOpenForSubmission:!1,hash:"9e8671bae09ccaa8b8e276c639a737fc",slug:"recent-advances-in-polynomials",bookSignature:"Kamal Shah",coverURL:"https://cdn.intechopen.com/books/images_new/10853.jpg",editedByType:"Edited by",publishedDate:"May 18th 2022",editors:[{id:"231748",title:"Dr.",name:"Kamal",middleName:null,surname:"Shah",slug:"kamal-shah",fullName:"Kamal Shah"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10871",title:"Computed-Tomography (CT) Scan",subtitle:null,isOpenForSubmission:!1,hash:"966d8cf74fa27eea1b9cbc9a6ee94993",slug:"computed-tomography-ct-scan",bookSignature:"Reda R. Gharieb",coverURL:"https://cdn.intechopen.com/books/images_new/10871.jpg",editedByType:"Edited by",publishedDate:"May 18th 2022",editors:[{id:"225387",title:"Prof.",name:"Reda R.",middleName:"R.",surname:"Gharieb",slug:"reda-r.-gharieb",fullName:"Reda R. Gharieb"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10903",title:"Genetically Modified Plants and Beyond",subtitle:null,isOpenForSubmission:!1,hash:"4d7ed4faab99c92cd4d676dc86501df9",slug:"genetically-modified-plants-and-beyond",bookSignature:"Idah Sithole Niang",coverURL:"https://cdn.intechopen.com/books/images_new/10903.jpg",editedByType:"Edited by",publishedDate:"May 18th 2022",editors:[{id:"90172",title:"Prof.",name:"Idah",middleName:null,surname:"Sithole-Niang",slug:"idah-sithole-niang",fullName:"Idah Sithole-Niang"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10904",title:"Fusarium",subtitle:"An Overview of the Genus",isOpenForSubmission:!1,hash:"49d9063e43f94bd1517d65fbc58b93c3",slug:"fusarium-an-overview-of-the-genus",bookSignature:"Seyed Mahyar Mirmajlessi",coverURL:"https://cdn.intechopen.com/books/images_new/10904.jpg",editedByType:"Edited by",publishedDate:"May 18th 2022",editors:[{id:"100573",title:"Dr.",name:"Seyed Mahyar",middleName:null,surname:"Mirmajlessi",slug:"seyed-mahyar-mirmajlessi",fullName:"Seyed Mahyar Mirmajlessi"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10654",title:"Brain-Computer Interface",subtitle:null,isOpenForSubmission:!1,hash:"a5308884068cc53ed31c6baba756857f",slug:"brain-computer-interface",bookSignature:"Vahid Asadpour",coverURL:"https://cdn.intechopen.com/books/images_new/10654.jpg",editedByType:"Edited by",publishedDate:"May 18th 2022",editors:[{id:"165328",title:"Dr.",name:"Vahid",middleName:null,surname:"Asadpour",slug:"vahid-asadpour",fullName:"Vahid Asadpour"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10676",title:"Recent Applications in Graph Theory",subtitle:null,isOpenForSubmission:!1,hash:"900c60742d224080732bd16bd25ccba8",slug:"recent-applications-in-graph-theory",bookSignature:"Harun Pirim",coverURL:"https://cdn.intechopen.com/books/images_new/10676.jpg",editedByType:"Edited by",publishedDate:"May 18th 2022",editors:[{id:"146092",title:"Dr.",name:"Harun",middleName:null,surname:"Pirim",slug:"harun-pirim",fullName:"Harun Pirim"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"11196",title:"New Updates in E-Learning",subtitle:null,isOpenForSubmission:!1,hash:"6afaadf68e2a0a4b370ac5ceb5ca89c6",slug:"new-updates-in-e-learning",bookSignature:"Eduard Babulak",coverURL:"https://cdn.intechopen.com/books/images_new/11196.jpg",editedByType:"Edited by",publishedDate:"May 18th 2022",editors:[{id:"10086",title:"Prof.",name:"Eduard",middleName:null,surname:"Babulak",slug:"eduard-babulak",fullName:"Eduard Babulak"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9974",title:"E-Learning and Digital Education in the Twenty-First Century",subtitle:null,isOpenForSubmission:!1,hash:"88b58d66e975df20425fc1dfd22d53aa",slug:"e-learning-and-digital-education-in-the-twenty-first-century",bookSignature:"M. Mahruf C. Shohel",coverURL:"https://cdn.intechopen.com/books/images_new/9974.jpg",editedByType:"Edited by",publishedDate:"May 18th 2022",editors:[{id:"94099",title:"Dr.",name:"M. Mahruf C.",middleName:null,surname:"Shohel",slug:"m.-mahruf-c.-shohel",fullName:"M. Mahruf C. Shohel"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}}]},subject:{topic:{id:"871",title:"Urban Ecology",slug:"urban-ecology",parent:{id:"136",title:"Environmental Sustainability",slug:"environmental-sciences-environmental-sustainability"},numberOfBooks:3,numberOfSeries:0,numberOfAuthorsAndEditors:95,numberOfWosCitations:51,numberOfCrossrefCitations:66,numberOfDimensionsCitations:121,videoUrl:null,fallbackUrl:null,description:null},booksByTopicFilter:{topicId:"871",sort:"-publishedDate",limit:12,offset:0},booksByTopicCollection:[{type:"book",id:"7831",title:"Sustainability in Urban Planning and Design",subtitle:null,isOpenForSubmission:!1,hash:"c924420492c8c2c9751e178d025f4066",slug:"sustainability-in-urban-planning-and-design",bookSignature:"Amjad Almusaed, Asaad Almssad and Linh Truong - Hong",coverURL:"https://cdn.intechopen.com/books/images_new/7831.jpg",editedByType:"Edited by",editors:[{id:"110471",title:"Prof.",name:"Amjad",middleName:"Zaki",surname:"Almusaed",slug:"amjad-almusaed",fullName:"Amjad Almusaed"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"8260",title:"Urban and Architectural Heritage Conservation within Sustainability",subtitle:null,isOpenForSubmission:!1,hash:"6594cc0ad7cb888bfdc4ac97c9a281f7",slug:"urban-and-architectural-heritage-conservation-within-sustainability",bookSignature:"Kabila Hmood",coverURL:"https://cdn.intechopen.com/books/images_new/8260.jpg",editedByType:"Edited by",editors:[{id:"214741",title:"Prof.",name:"Dr. Kabila",middleName:"Faris",surname:"Hmood",slug:"dr.-kabila-hmood",fullName:"Dr. Kabila Hmood"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"5235",title:"Sustainable Urbanization",subtitle:null,isOpenForSubmission:!1,hash:"76200e89c8c93b3c0b22062aa09a84ff",slug:"sustainable-urbanization",bookSignature:"Mustafa Ergen",coverURL:"https://cdn.intechopen.com/books/images_new/5235.jpg",editedByType:"Edited by",editors:[{id:"166961",title:"Dr.Ing.",name:"Mustafa",middleName:null,surname:"Ergen",slug:"mustafa-ergen",fullName:"Mustafa Ergen"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}}],booksByTopicTotal:3,seriesByTopicCollection:[],seriesByTopicTotal:0,mostCitedChapters:[{id:"64381",doi:"10.5772/intechopen.82025",title:"Sustainability and Vernacular Architecture: Rethinking What Identity Is",slug:"sustainability-and-vernacular-architecture-rethinking-what-identity-is",totalDownloads:4330,totalCrossrefCites:7,totalDimensionsCites:20,abstract:"Sustainability has often been a fundamental part of the composition of both tangible and intangible cultural resources; sustainability and preservation of cultural identity are complementary. Elements of sustainable design are integral to vernacular architecture that have evolved over time using local materials and technology emerging from ambient natural and cultural environment creating optimum relationships between people and their place. This chapter aims to redefine what identity is as a concept and the impact of globalization on contemporary architecture especially on regions with rich heritage and unique culture as the Arab World. To accomplish this, the chapter examines the emergence of “local identity” as a reaction to the globalization of cultural values, uniform architectural styles, and stereotype patterns through discussing sustainability as a motivation for identity in culture and architecture. The research methodology is based on conducting a qualitative analysis of literature review to the main concepts discussed in this chapter such as: identity, culture, vernacular architecture, and sustainability. Through comparative analysis, the chapter investigates sustainability potential of vernacular architecture in the region to derive core concepts as guidelines of reproducing the characteristics of society and reveal identity of contemporary architecture in the Arab World.",book:{id:"8260",slug:"urban-and-architectural-heritage-conservation-within-sustainability",title:"Urban and Architectural Heritage Conservation within Sustainability",fullTitle:"Urban and Architectural Heritage Conservation within Sustainability"},signatures:"Maha Salman",authors:[{id:"258226",title:"Dr.",name:"Maha",middleName:null,surname:"Salman",slug:"maha-salman",fullName:"Maha Salman"}]},{id:"51000",doi:"10.5772/63726",title:"Towards Sustainable Sanitation in an Urbanising World",slug:"towards-sustainable-sanitation-in-an-urbanising-world",totalDownloads:3157,totalCrossrefCites:11,totalDimensionsCites:17,abstract:"Urban sanitation in low‐ and middle‐income countries is at an inflection point. It is increasingly acknowledged that conventional sewer‐based sanitation cannot be the only solution for expanding urban areas. There are other objective reasons apart from the lack of capital. The lack of stable energy supplies, of spare parts and of human resources for reliable operation, and the increasing water scarcity are factors that seriously limit the expansion of centralised systems. This chapter argues that a new paradigm for urban sanitation is possible, if the heterogeneity within developing cities is reflected in the implementation of different sanitation systems, adapted to each urban context and integrated under one institutional roof. This new paradigm entails: (1) innovative management arrangements; (2) increased participation and the integration of individual, community and private sector initiatives; (3) thinking at scale to open new opportunities; (4) improved analysis of the situation and awareness raising. Moving beyond conventional approaches towards sustainable urbanisation needs to follow both a top‐down and a bottom‐up approach, with proper incentives and a variety of sanitation systems which, in a future perspective, will become part of the ‘urban ecosystem’.",book:{id:"5235",slug:"sustainable-urbanization",title:"Sustainable Urbanization",fullTitle:"Sustainable Urbanization"},signatures:"Philippe Reymond, Samuel Renggli and Christoph Lüthi",authors:[{id:"181079",title:"Dr.",name:"Christoph",middleName:null,surname:"Lüthi",slug:"christoph-luthi",fullName:"Christoph Lüthi"},{id:"182136",title:"Mr.",name:"Philippe",middleName:null,surname:"Reymond",slug:"philippe-reymond",fullName:"Philippe Reymond"},{id:"182137",title:"Mr.",name:"Samuel",middleName:null,surname:"Renggli",slug:"samuel-renggli",fullName:"Samuel Renggli"}]},{id:"70410",doi:"10.5772/intechopen.89617",title:"New Metrics for Spatial and Temporal 3D Urban Form Sustainability Assessment Using Time Series Lidar Point Clouds and Advanced GIS Techniques",slug:"new-metrics-for-spatial-and-temporal-3d-urban-form-sustainability-assessment-using-time-series-lidar",totalDownloads:748,totalCrossrefCites:4,totalDimensionsCites:8,abstract:"Monitoring sustainability of urban form as a 3D phenomenon over time is crucial in the era of smart cities for better planning of the future, and for such a monitoring system, appropriate tools, metrics, methodologies and time series 3D data are required. While accurate time series 3D data are becoming available, a lack of 3D sustainable urban form (3D SUF) metrics, appropriate methodologies and technical problems of processing time series 3D data has resulted in few studies on the assessment of 3D SUF over time. In this chapter, we review volumetric building metrics currently under development and demonstrate the technical problems associated with their validation based on time series airborne lidar data. We propose new metrics for application in spatial and temporal 3D SUF assessment. We also suggest a new approach in processing time series airborne lidar to detect three-dimensional changes of urban form. Using this approach and the developed metrics, we detected a decreased volume of vegetation and new areas prepared for the construction of taller buildings. These 3D changes and the proposed metrics can be used to numerically measure and compare urban areas in terms of trends against or in favor of sustainability goals for caring for the environment.",book:{id:"7831",slug:"sustainability-in-urban-planning-and-design",title:"Sustainability in Urban Planning and Design",fullTitle:"Sustainability in Urban Planning and Design"},signatures:"Sara Shirowzhan, John Trinder and Paul Osmond",authors:[{id:"267958",title:"Prof.",name:"John",middleName:null,surname:"Trinder",slug:"john-trinder",fullName:"John Trinder"},{id:"273838",title:"Dr.",name:"Sara",middleName:null,surname:"Shirowzhan",slug:"sara-shirowzhan",fullName:"Sara Shirowzhan"},{id:"295989",title:"Prof.",name:"Paul",middleName:null,surname:"Osmond",slug:"paul-osmond",fullName:"Paul Osmond"}]},{id:"50306",doi:"10.5772/62784",title:"Landscape Ecology Practices in Planning: Landscape Connectivity and Urban Networks",slug:"landscape-ecology-practices-in-planning-landscape-connectivity-and-urban-networks",totalDownloads:2216,totalCrossrefCites:3,totalDimensionsCites:7,abstract:"The increasing need to conserve the nature and biodiversity and to maintain human well-being has motivated landscape planners and researchers to seek different planning approaches in urban environments. In this context, different approaches to planning urban networks have been developed to promote the sustainable use and functioning of landscapes, to conserve the nature and species, and increase its use and enjoyment by people [1, 2]. In principle, these approaches have been founded on the conservation of natural areas/biodiversity and with a consensus on their benefits to nature, biodiversity and people [3–5]. However, they generally differ from each other with respect to their expected aims, and ecological and/or social functions [6]. Therefore, by examining different planning approaches to networks, this chapter clarifies what is meant by these concepts and approaches in the literature.",book:{id:"5235",slug:"sustainable-urbanization",title:"Sustainable Urbanization",fullTitle:"Sustainable Urbanization"},signatures:"Ebru Ersoy",authors:[{id:"182298",title:"Dr.",name:"Ebru",middleName:null,surname:"Ersoy",slug:"ebru-ersoy",fullName:"Ebru Ersoy"}]},{id:"67342",doi:"10.5772/intechopen.86670",title:"Introductory Chapter: Heritage Conservation - Rehabilitation of Architectural and Urban Heritage",slug:"introductory-chapter-heritage-conservation-rehabilitation-of-architectural-and-urban-heritage",totalDownloads:2477,totalCrossrefCites:3,totalDimensionsCites:6,abstract:null,book:{id:"8260",slug:"urban-and-architectural-heritage-conservation-within-sustainability",title:"Urban and Architectural Heritage Conservation within Sustainability",fullTitle:"Urban and Architectural Heritage Conservation within Sustainability"},signatures:"Kabila Faris Hmood",authors:[{id:"214741",title:"Prof.",name:"Dr. Kabila",middleName:"Faris",surname:"Hmood",slug:"dr.-kabila-hmood",fullName:"Dr. Kabila Hmood"}]}],mostDownloadedChaptersLast30Days:[{id:"64381",title:"Sustainability and Vernacular Architecture: Rethinking What Identity Is",slug:"sustainability-and-vernacular-architecture-rethinking-what-identity-is",totalDownloads:4330,totalCrossrefCites:7,totalDimensionsCites:20,abstract:"Sustainability has often been a fundamental part of the composition of both tangible and intangible cultural resources; sustainability and preservation of cultural identity are complementary. Elements of sustainable design are integral to vernacular architecture that have evolved over time using local materials and technology emerging from ambient natural and cultural environment creating optimum relationships between people and their place. This chapter aims to redefine what identity is as a concept and the impact of globalization on contemporary architecture especially on regions with rich heritage and unique culture as the Arab World. To accomplish this, the chapter examines the emergence of “local identity” as a reaction to the globalization of cultural values, uniform architectural styles, and stereotype patterns through discussing sustainability as a motivation for identity in culture and architecture. The research methodology is based on conducting a qualitative analysis of literature review to the main concepts discussed in this chapter such as: identity, culture, vernacular architecture, and sustainability. Through comparative analysis, the chapter investigates sustainability potential of vernacular architecture in the region to derive core concepts as guidelines of reproducing the characteristics of society and reveal identity of contemporary architecture in the Arab World.",book:{id:"8260",slug:"urban-and-architectural-heritage-conservation-within-sustainability",title:"Urban and Architectural Heritage Conservation within Sustainability",fullTitle:"Urban and Architectural Heritage Conservation within Sustainability"},signatures:"Maha Salman",authors:[{id:"258226",title:"Dr.",name:"Maha",middleName:null,surname:"Salman",slug:"maha-salman",fullName:"Maha Salman"}]},{id:"67342",title:"Introductory Chapter: Heritage Conservation - Rehabilitation of Architectural and Urban Heritage",slug:"introductory-chapter-heritage-conservation-rehabilitation-of-architectural-and-urban-heritage",totalDownloads:2478,totalCrossrefCites:3,totalDimensionsCites:6,abstract:null,book:{id:"8260",slug:"urban-and-architectural-heritage-conservation-within-sustainability",title:"Urban and Architectural Heritage Conservation within Sustainability",fullTitle:"Urban and Architectural Heritage Conservation within Sustainability"},signatures:"Kabila Faris Hmood",authors:[{id:"214741",title:"Prof.",name:"Dr. Kabila",middleName:"Faris",surname:"Hmood",slug:"dr.-kabila-hmood",fullName:"Dr. Kabila Hmood"}]},{id:"50282",title:"Relation Between Land Use and Transportation Planning in the Scope of Smart Growth Strategies: Case Study of Denizli, Turkey",slug:"relation-between-land-use-and-transportation-planning-in-the-scope-of-smart-growth-strategies-case-s",totalDownloads:4614,totalCrossrefCites:0,totalDimensionsCites:1,abstract:"In the decision-making process of planning residential areas in developing countries, importance of the commercial areas and need for a sustainable urban transportation infrastructure have generally been ignored based on several sociopolitical reasons. Meanwhile, decision-making periods of location choice and determining areal densities are conducted without quantitative spatial/technical analyses. Those urban matters bring along new planning paradigms like smart growth (SG) and new urbanism. SG is a land use planning paradigm which indicates that traffic problems should be minimized by transit alternatives, effective demand management and providing a balance between land use and transportation planning. This study aims to apply SG strategies to the land use planning process and evaluate the accuracy of land use planning decisions in the perspective of sustainable transportation. In order to reveal the effects of land use planning decisions on the available transportation infrastructure, two scenarios are investigated for 2030. In the first scenario “do nothing” option is considered, while the residential area densities and trip generation rates are regulated based on SG strategies in the second scenario. The results showed that the land use and traffic impact analyses should simultaneously be conducted before land use configuration process.",book:{id:"5235",slug:"sustainable-urbanization",title:"Sustainable Urbanization",fullTitle:"Sustainable Urbanization"},signatures:"Gorkem Gulhan and Huseyin Ceylan",authors:[{id:"182126",title:"Dr.",name:"Gorkem",middleName:null,surname:"Gulhan",slug:"gorkem-gulhan",fullName:"Gorkem Gulhan"},{id:"185555",title:"Dr.",name:"Huseyin",middleName:null,surname:"Ceylan",slug:"huseyin-ceylan",fullName:"Huseyin Ceylan"}]},{id:"70567",title:"City Phenomenon between Urban Structure and Composition",slug:"city-phenomenon-between-urban-structure-and-composition",totalDownloads:1544,totalCrossrefCites:5,totalDimensionsCites:5,abstract:"Cities are not just a sum of buildings, but especially a set of social relations that their inhabitants develop. Cities are characterized by a wide variety of social groups and lifestyles. An urban composition represents a form of the city in which it gets a formal order, so that the shape of any urban ensemble is not linked to a random phenomenon, but to an intervention mastered and understood as such. For the city, the urban composition represents what the architectural composition represents for a building. This concept regarding the composition is common both to the architecture and to the city. The main property of the composition is that it transforms a possibly dispersed ensemble into a whole, resolving the contradictions that arise when the requirements and conditions of the project are numerous. Spatial forms and urban compositions are built over time, longer than that of architectural composition. On the other hand, “design of the urban environment” is understood by us as a complex formation of public spaces of the city, located on the ground floor level of the city building and ensuring the vital activity of the urban community. This chapter will study the city phenomenon on a large scale.",book:{id:"7831",slug:"sustainability-in-urban-planning-and-design",title:"Sustainability in Urban Planning and Design",fullTitle:"Sustainability in Urban Planning and Design"},signatures:"Amjad Almusaed and Asaad Almssad",authors:[{id:"110471",title:"Prof.",name:"Amjad",middleName:"Zaki",surname:"Almusaed",slug:"amjad-almusaed",fullName:"Amjad Almusaed"},{id:"194040",title:"Prof.",name:"Asaad",middleName:null,surname:"Almssad",slug:"asaad-almssad",fullName:"Asaad Almssad"}]},{id:"68452",title:"Lessons from Baghdad City Conformation and Essence",slug:"lessons-from-baghdad-city-conformation-and-essence",totalDownloads:1211,totalCrossrefCites:2,totalDimensionsCites:4,abstract:"This chapter aims to address the emergence of Baghdad and the phases of its morphology and transformation. The first era began with the Round City; this originated the first nucleus that later formed Baghdad. The historical parts of most Middle Eastern old cities usually occupy polar places in relation to the rest of their city zones. These historical centres can give a city its own identity and embody exceptional urban assets, if carefully maintained and managed. In this chapter, there are two significant periods, the Abbasid Empire and post-Abbasid Empire. One of the main concerns is the conflict between two trends, old fabric as a traditional pattern and modern thoughts and, consequently, how that could affect in formulating the development plan.",book:{id:"7831",slug:"sustainability-in-urban-planning-and-design",title:"Sustainability in Urban Planning and Design",fullTitle:"Sustainability in Urban Planning and Design"},signatures:"Haider J.E. Al-Saaidy",authors:[{id:"304091",title:"Dr.",name:"Haider",middleName:"Jasim Essa",surname:"Al-Saaidy",slug:"haider-al-saaidy",fullName:"Haider Al-Saaidy"}]}],onlineFirstChaptersFilter:{topicId:"871",limit:6,offset:0},onlineFirstChaptersCollection:[],onlineFirstChaptersTotal:0},preDownload:{success:null,errors:{}},subscriptionForm:{success:null,errors:{}},aboutIntechopen:{},privacyPolicy:{},peerReviewing:{},howOpenAccessPublishingWithIntechopenWorks:{},sponsorshipBooks:{sponsorshipBooks:[],offset:8,limit:8,total:0},allSeries:{pteSeriesList:[{id:"14",title:"Artificial Intelligence",numberOfPublishedBooks:9,numberOfPublishedChapters:87,numberOfOpenTopics:6,numberOfUpcomingTopics:0,issn:"2633-1403",doi:"10.5772/intechopen.79920",isOpenForSubmission:!0},{id:"7",title:"Biomedical Engineering",numberOfPublishedBooks:12,numberOfPublishedChapters:98,numberOfOpenTopics:3,numberOfUpcomingTopics:0,issn:"2631-5343",doi:"10.5772/intechopen.71985",isOpenForSubmission:!0}],lsSeriesList:[{id:"11",title:"Biochemistry",numberOfPublishedBooks:27,numberOfPublishedChapters:287,numberOfOpenTopics:4,numberOfUpcomingTopics:0,issn:"2632-0983",doi:"10.5772/intechopen.72877",isOpenForSubmission:!0},{id:"25",title:"Environmental Sciences",numberOfPublishedBooks:1,numberOfPublishedChapters:9,numberOfOpenTopics:4,numberOfUpcomingTopics:0,issn:"2754-6713",doi:"10.5772/intechopen.100362",isOpenForSubmission:!0},{id:"10",title:"Physiology",numberOfPublishedBooks:11,numberOfPublishedChapters:139,numberOfOpenTopics:4,numberOfUpcomingTopics:0,issn:"2631-8261",doi:"10.5772/intechopen.72796",isOpenForSubmission:!0}],hsSeriesList:[{id:"3",title:"Dentistry",numberOfPublishedBooks:8,numberOfPublishedChapters:129,numberOfOpenTopics:0,numberOfUpcomingTopics:2,issn:"2631-6218",doi:"10.5772/intechopen.71199",isOpenForSubmission:!1},{id:"6",title:"Infectious Diseases",numberOfPublishedBooks:13,numberOfPublishedChapters:107,numberOfOpenTopics:3,numberOfUpcomingTopics:1,issn:"2631-6188",doi:"10.5772/intechopen.71852",isOpenForSubmission:!0},{id:"13",title:"Veterinary Medicine and Science",numberOfPublishedBooks:10,numberOfPublishedChapters:103,numberOfOpenTopics:3,numberOfUpcomingTopics:0,issn:"2632-0517",doi:"10.5772/intechopen.73681",isOpenForSubmission:!0}],sshSeriesList:[{id:"22",title:"Business, Management and Economics",numberOfPublishedBooks:1,numberOfPublishedChapters:12,numberOfOpenTopics:2,numberOfUpcomingTopics:1,issn:null,doi:"10.5772/intechopen.100359",isOpenForSubmission:!0},{id:"23",title:"Education and Human Development",numberOfPublishedBooks:0,numberOfPublishedChapters:0,numberOfOpenTopics:2,numberOfUpcomingTopics:0,issn:null,doi:"10.5772/intechopen.100360",isOpenForSubmission:!1},{id:"24",title:"Sustainable Development",numberOfPublishedBooks:0,numberOfPublishedChapters:10,numberOfOpenTopics:4,numberOfUpcomingTopics:1,issn:null,doi:"10.5772/intechopen.100361",isOpenForSubmission:!0}],testimonialsList:[{id:"13",text:"The collaboration with and support of the technical staff of IntechOpen is fantastic. The whole process of submitting an article and editing of the submitted article goes extremely smooth and fast, the number of reads and downloads of chapters is high, and the contributions are also frequently cited.",author:{id:"55578",name:"Antonio",surname:"Jurado-Navas",institutionString:null,profilePictureURL:"https://s3.us-east-1.amazonaws.com/intech-files/0030O00002bRisIQAS/Profile_Picture_1626166543950",slug:"antonio-jurado-navas",institution:{id:"720",name:"University of Malaga",country:{id:null,name:"Spain"}}}},{id:"6",text:"It is great to work with the IntechOpen to produce a worthwhile collection of research that also becomes a great educational resource and guide for future research endeavors.",author:{id:"259298",name:"Edward",surname:"Narayan",institutionString:null,profilePictureURL:"https://mts.intechopen.com/storage/users/259298/images/system/259298.jpeg",slug:"edward-narayan",institution:{id:"3",name:"University of Queensland",country:{id:null,name:"Australia"}}}}]},series:{item:{id:"13",title:"Veterinary Medicine and Science",doi:"10.5772/intechopen.73681",issn:"2632-0517",scope:"Paralleling similar advances in the medical field, astounding advances occurred in Veterinary Medicine and Science in recent decades. These advances have helped foster better support for animal health, more humane animal production, and a better understanding of the physiology of endangered species to improve the assisted reproductive technologies or the pathogenesis of certain diseases, where animals can be used as models for human diseases (like cancer, degenerative diseases or fertility), and even as a guarantee of public health. Bridging Human, Animal, and Environmental health, the holistic and integrative “One Health” concept intimately associates the developments within those fields, projecting its advancements into practice. This book series aims to tackle various animal-related medicine and sciences fields, providing thematic volumes consisting of high-quality significant research directed to researchers and postgraduates. It aims to give us a glimpse into the new accomplishments in the Veterinary Medicine and Science field. By addressing hot topics in veterinary sciences, we aim to gather authoritative texts within each issue of this series, providing in-depth overviews and analysis for graduates, academics, and practitioners and foreseeing a deeper understanding of the subject. Forthcoming texts, written and edited by experienced researchers from both industry and academia, will also discuss scientific challenges faced today in Veterinary Medicine and Science. In brief, we hope that books in this series will provide accessible references for those interested or working in this field and encourage learning in a range of different topics.",coverUrl:"https://cdn.intechopen.com/series/covers/13.jpg",latestPublicationDate:"May 18th, 2022",hasOnlineFirst:!0,numberOfPublishedBooks:10,editor:{id:"38652",title:"Dr.",name:"Rita",middleName:null,surname:"Payan-Carreira",slug:"rita-payan-carreira",fullName:"Rita Payan-Carreira",profilePictureURL:"https://s3.us-east-1.amazonaws.com/intech-files/0030O00002bRiFPQA0/Profile_Picture_1614601496313",biography:"Rita Payan Carreira earned her Veterinary Degree from the Faculty of Veterinary Medicine in Lisbon, Portugal, in 1985. She obtained her Ph.D. in Veterinary Sciences from the University of Trás-os-Montes e Alto Douro, Portugal. After almost 32 years of teaching at the University of Trás-os-Montes and Alto Douro, she recently moved to the University of Évora, Department of Veterinary Medicine, where she teaches in the field of Animal Reproduction and Clinics. Her primary research areas include the molecular markers of the endometrial cycle and the embryo–maternal interaction, including oxidative stress and the reproductive physiology and disorders of sexual development, besides the molecular determinants of male and female fertility. She often supervises students preparing their master's or doctoral theses. She is also a frequent referee for various journals.",institutionString:null,institution:{name:"University of Évora",institutionURL:null,country:{name:"Portugal"}}},editorTwo:null,editorThree:null},subseries:{paginationCount:3,paginationItems:[{id:"19",title:"Animal Science",coverUrl:"https://cdn.intechopen.com/series_topics/covers/19.jpg",isOpenForSubmission:!0,editor:{id:"259298",title:"Dr.",name:"Edward",middleName:null,surname:"Narayan",slug:"edward-narayan",fullName:"Edward Narayan",profilePictureURL:"https://mts.intechopen.com/storage/users/259298/images/system/259298.jpeg",biography:"Dr. Edward Narayan graduated with Ph.D. degree in Biology from the University of the South Pacific and pioneered non-invasive reproductive and stress endocrinology tools for amphibians - the novel development and validation of non-invasive enzyme immunoassays for the evaluation of reproductive hormonal cycle and stress hormone responses to environmental stressors. \nDr. Narayan leads the Stress Lab (Comparative Physiology and Endocrinology) at the University of Queensland. A dynamic career research platform which is based on the thematic areas of comparative vertebrate physiology, stress endocrinology, reproductive endocrinology, animal health and welfare, and conservation biology. \nEdward has supervised 40 research students and published over 60 peer reviewed research.",institutionString:null,institution:{name:"University of Queensland",institutionURL:null,country:{name:"Australia"}}},editorTwo:null,editorThree:null},{id:"20",title:"Animal Nutrition",coverUrl:"https://cdn.intechopen.com/series_topics/covers/20.jpg",isOpenForSubmission:!0,editor:{id:"175967",title:"Dr.",name:"Manuel",middleName:null,surname:"Gonzalez Ronquillo",slug:"manuel-gonzalez-ronquillo",fullName:"Manuel Gonzalez Ronquillo",profilePictureURL:"https://mts.intechopen.com/storage/users/175967/images/system/175967.png",biography:"Dr. Manuel González Ronquillo obtained his doctorate degree from the University of Zaragoza, Spain, in 2001. He is a research professor at the Faculty of Veterinary Medicine and Animal Husbandry, Autonomous University of the State of Mexico. He is also a level-2 researcher. He received a Fulbright-Garcia Robles fellowship for a postdoctoral stay at the US Dairy Forage Research Center, Madison, Wisconsin, USA in 2008–2009. He received grants from Alianza del Pacifico for a stay at the University of Magallanes, Chile, in 2014, and from Consejo Nacional de Ciencia y Tecnología (CONACyT) to work in the Food and Agriculture Organization’s Animal Production and Health Division (AGA), Rome, Italy, in 2014–2015. He has collaborated with researchers from different countries and published ninety-eight journal articles. He teaches various degree courses in zootechnics, sheep production, and agricultural sciences and natural resources.\n\nDr. Ronquillo’s research focuses on the evaluation of sustainable animal diets (StAnD), using native resources of the region, decreasing carbon footprint, and applying meta-analysis and mathematical models for a better understanding of animal production.",institutionString:null,institution:{name:"Universidad Autónoma del Estado de México",institutionURL:null,country:{name:"Mexico"}}},editorTwo:null,editorThree:null},{id:"28",title:"Animal Reproductive Biology and Technology",coverUrl:"https://cdn.intechopen.com/series_topics/covers/28.jpg",isOpenForSubmission:!0,editor:{id:"177225",title:"Prof.",name:"Rosa Maria Lino Neto",middleName:null,surname:"Pereira",slug:"rosa-maria-lino-neto-pereira",fullName:"Rosa Maria Lino Neto Pereira",profilePictureURL:"https://s3.us-east-1.amazonaws.com/intech-files/0030O00002bS9wkQAC/Profile_Picture_1624519982291",biography:"Rosa Maria Lino Neto Pereira (DVM, MsC, PhD and) is currently a researcher at the Genetic Resources and Biotechnology Unit of the National Institute of Agrarian and Veterinarian Research (INIAV, Portugal). She is the head of the Reproduction and Embryology Laboratories and was lecturer of Reproduction and Reproductive Biotechnologies at Veterinary Medicine Faculty. She has over 25 years of experience working in reproductive biology and biotechnology areas with a special emphasis on embryo and gamete cryopreservation, for research and animal genetic resources conservation, leading research projects with several peer-reviewed papers. Rosa Pereira is member of the ERFP-FAO Ex situ Working Group and of the Management Commission of the Portuguese Animal Germplasm Bank.",institutionString:"The National Institute for Agricultural and Veterinary Research. Portugal",institution:null},editorTwo:null,editorThree:null}]},overviewPageOFChapters:{paginationCount:19,paginationItems:[{id:"81793",title:"Canine parvovirus-2: An Emerging Threat to Young Pets",doi:"10.5772/intechopen.104846",signatures:"Mithilesh Singh, Rajendran Manikandan, Ujjwal Kumar De, Vishal Chander, Babul Rudra Paul, Saravanan Ramakrishnan and Darshini Maramreddy",slug:"canine-parvovirus-2-an-emerging-threat-to-young-pets",totalDownloads:4,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Recent Advances in Canine Medicine",coverURL:"https://cdn.intechopen.com/books/images_new/11580.jpg",subseries:{id:"19",title:"Animal Science"}}},{id:"81271",title:"The Diversity of Parvovirus Telomeres",doi:"10.5772/intechopen.102684",signatures:"Marianne Laugel, Emilie Lecomte, Eduard Ayuso, Oumeya Adjali, Mathieu Mével and Magalie Penaud-Budloo",slug:"the-diversity-of-parvovirus-telomeres",totalDownloads:23,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Recent Advances in Canine Medicine",coverURL:"https://cdn.intechopen.com/books/images_new/11580.jpg",subseries:{id:"19",title:"Animal Science"}}},{id:"79909",title:"Cryopreservation Methods and Frontiers in the Art of Freezing Life in Animal Models",doi:"10.5772/intechopen.101750",signatures:"Feda S. Aljaser",slug:"cryopreservation-methods-and-frontiers-in-the-art-of-freezing-life-in-animal-models",totalDownloads:163,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Animal Reproduction",coverURL:"https://cdn.intechopen.com/books/images_new/10664.jpg",subseries:{id:"28",title:"Animal Reproductive Biology and Technology"}}},{id:"79782",title:"Avian Reproduction",doi:"10.5772/intechopen.101185",signatures:"Kingsley Omogiade Idahor",slug:"avian-reproduction",totalDownloads:149,totalCrossrefCites:0,totalDimensionsCites:0,authors:[{name:"Kingsley O.",surname:"Idahor"}],book:{title:"Animal Reproduction",coverURL:"https://cdn.intechopen.com/books/images_new/10664.jpg",subseries:{id:"28",title:"Animal Reproductive Biology and Technology"}}}]},overviewPagePublishedBooks:{paginationCount:10,paginationItems:[{type:"book",id:"7233",title:"New Insights into Theriogenology",subtitle:null,coverURL:"https://cdn.intechopen.com/books/images_new/7233.jpg",slug:"new-insights-into-theriogenology",publishedDate:"December 5th 2018",editedByType:"Edited by",bookSignature:"Rita Payan-Carreira",hash:"74f4147e3fb214dd050e5edd3aaf53bc",volumeInSeries:1,fullTitle:"New Insights into Theriogenology",editors:[{id:"38652",title:"Dr.",name:"Rita",middleName:null,surname:"Payan-Carreira",slug:"rita-payan-carreira",fullName:"Rita Payan-Carreira",profilePictureURL:"https://s3.us-east-1.amazonaws.com/intech-files/0030O00002bRiFPQA0/Profile_Picture_1614601496313",biography:"Rita Payan Carreira earned her Veterinary Degree from the Faculty of Veterinary Medicine in Lisbon, Portugal, in 1985. She obtained her Ph.D. in Veterinary Sciences from the University of Trás-os-Montes e Alto Douro, Portugal. After almost 32 years of teaching at the University of Trás-os-Montes and Alto Douro, she recently moved to the University of Évora, Department of Veterinary Medicine, where she teaches in the field of Animal Reproduction and Clinics. Her primary research areas include the molecular markers of the endometrial cycle and the embryo–maternal interaction, including oxidative stress and the reproductive physiology and disorders of sexual development, besides the molecular determinants of male and female fertility. She often supervises students preparing their master's or doctoral theses. She is also a frequent referee for various journals.",institutionString:null,institution:{name:"University of Évora",institutionURL:null,country:{name:"Portugal"}}}]},{type:"book",id:"7144",title:"Veterinary Anatomy and Physiology",subtitle:null,coverURL:"https://cdn.intechopen.com/books/images_new/7144.jpg",slug:"veterinary-anatomy-and-physiology",publishedDate:"March 13th 2019",editedByType:"Edited by",bookSignature:"Catrin Sian Rutland and Valentina Kubale",hash:"75cdacb570e0e6d15a5f6e69640d87c9",volumeInSeries:2,fullTitle:"Veterinary Anatomy and Physiology",editors:[{id:"202192",title:"Dr.",name:"Catrin",middleName:null,surname:"Rutland",slug:"catrin-rutland",fullName:"Catrin Rutland",profilePictureURL:"https://mts.intechopen.com/storage/users/202192/images/system/202192.png",biography:"Catrin Rutland is an Associate Professor of Anatomy and Developmental Genetics at the University of Nottingham, UK. She obtained a BSc from the University of Derby, England, a master’s degree from Technische Universität München, Germany, and a Ph.D. from the University of Nottingham. She undertook a post-doctoral research fellowship in the School of Medicine before accepting tenure in Veterinary Medicine and Science. Dr. Rutland also obtained an MMedSci (Medical Education) and a Postgraduate Certificate in Higher Education (PGCHE). She is the author of more than sixty peer-reviewed journal articles, twelve books/book chapters, and more than 100 research abstracts in cardiovascular biology and oncology. She is a board member of the European Association of Veterinary Anatomists, Fellow of the Anatomical Society, and Senior Fellow of the Higher Education Academy. Dr. Rutland has also written popular science books for the public. https://orcid.org/0000-0002-2009-4898. www.nottingham.ac.uk/vet/people/catrin.rutland",institutionString:null,institution:{name:"University of Nottingham",institutionURL:null,country:{name:"United Kingdom"}}}]},{type:"book",id:"8524",title:"Lactation in Farm Animals",subtitle:"Biology, Physiological Basis, Nutritional Requirements, and Modelization",coverURL:"https://cdn.intechopen.com/books/images_new/8524.jpg",slug:"lactation-in-farm-animals-biology-physiological-basis-nutritional-requirements-and-modelization",publishedDate:"January 22nd 2020",editedByType:"Edited by",bookSignature:"Naceur M'Hamdi",hash:"2aa2a9a0ec13040bbf0455e34625504e",volumeInSeries:3,fullTitle:"Lactation in Farm Animals - Biology, Physiological Basis, Nutritional Requirements, and Modelization",editors:[{id:"73376",title:"Dr.",name:"Naceur",middleName:null,surname:"M'Hamdi",slug:"naceur-m'hamdi",fullName:"Naceur M'Hamdi",profilePictureURL:"https://mts.intechopen.com/storage/users/73376/images/system/73376.jpg",biography:"Naceur M’HAMDI is Associate Professor at the National Agronomic Institute of Tunisia, University of Carthage. He is also Member of the Laboratory of genetic, animal and feed resource and member of Animal science Department of INAT. He graduated from Higher School of Agriculture of Mateur, University of Carthage, in 2002 and completed his masters in 2006. Dr. M’HAMDI completed his PhD thesis in Genetic welfare indicators of dairy cattle at Higher Institute of Agronomy of Chott-Meriem, University of Sousse, in 2011. He worked as assistant Professor of Genetic, biostatistics and animal biotechnology at INAT since 2013.",institutionString:null,institution:null}]},{type:"book",id:"8460",title:"Reproductive Biology and Technology in Animals",subtitle:null,coverURL:"https://cdn.intechopen.com/books/images_new/8460.jpg",slug:"reproductive-biology-and-technology-in-animals",publishedDate:"April 15th 2020",editedByType:"Edited by",bookSignature:"Juan Carlos Gardón Poggi and Katy Satué Ambrojo",hash:"32ef5fe73998dd723d308225d756fa1e",volumeInSeries:4,fullTitle:"Reproductive Biology and Technology in Animals",editors:[{id:"251314",title:"Dr.",name:"Juan Carlos",middleName:null,surname:"Gardón",slug:"juan-carlos-gardon",fullName:"Juan Carlos Gardón",profilePictureURL:"https://mts.intechopen.com/storage/users/251314/images/system/251314.jpeg",biography:"Juan Carlos Gardón Poggi received University degree from the Faculty of Agrarian Science in Argentina, in 1983. Also he received Masters Degree and PhD from Córdoba University, Spain. He is currently a Professor at the Catholic University of Valencia San Vicente Mártir, at the Department of Medicine and Animal Surgery. He teaches diverse courses in the field of Animal Reproduction and he is the Director of the Veterinary Farm. He also participates in academic postgraduate activities at the Veterinary Faculty of Murcia University, Spain. His research areas include animal physiology, physiology and biotechnology of reproduction either in males or females, the study of gametes under in vitro conditions and the use of ultrasound as a complement to physiological studies and development of applied biotechnologies. Routinely, he supervises students preparing their doctoral, master thesis or final degree projects.",institutionString:"Catholic University of Valencia San Vicente Mártir, Spain",institution:null}]}]},openForSubmissionBooks:{paginationCount:2,paginationItems:[{id:"11603",title:"People Management - Highlighting Futures",coverURL:"https://cdn.intechopen.com/books/images_new/11603.jpg",hash:"982c56a5fb4684d966f8f5e76b2638f5",secondStepPassed:!0,currentStepOfPublishingProcess:3,submissionDeadline:"March 22nd 2022",isOpenForSubmission:!0,editors:[{id:"450553",title:"Prof.",name:"Diana",surname:"Dias",slug:"diana-dias",fullName:"Diana Dias"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null},{id:"11601",title:"Econometrics - Recent Advances and Applications",coverURL:"https://cdn.intechopen.com/books/images_new/11601.jpg",hash:"bc8ab49e2cf436c217a49ca8c12a22eb",secondStepPassed:!0,currentStepOfPublishingProcess:3,submissionDeadline:"May 13th 2022",isOpenForSubmission:!0,editors:[{id:"452331",title:"Dr.",name:"Brian",surname:"Sloboda",slug:"brian-sloboda",fullName:"Brian Sloboda"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null}]},onlineFirstChapters:{paginationCount:49,paginationItems:[{id:"80495",title:"Iron in Cell Metabolism and Disease",doi:"10.5772/intechopen.101908",signatures:"Eeka Prabhakar",slug:"iron-in-cell-metabolism-and-disease",totalDownloads:2,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Iron Metabolism - Iron a Double‐Edged Sword",coverURL:"https://cdn.intechopen.com/books/images_new/10842.jpg",subseries:{id:"17",title:"Metabolism"}}},{id:"81799",title:"Cross Talk of Purinergic and Immune Signaling: Implication in Inflammatory and Pathogenic Diseases",doi:"10.5772/intechopen.104978",signatures:"Richa Rai",slug:"cross-talk-of-purinergic-and-immune-signaling-implication-in-inflammatory-and-pathogenic-diseases",totalDownloads:7,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Purinergic System",coverURL:"https://cdn.intechopen.com/books/images_new/10801.jpg",subseries:{id:"17",title:"Metabolism"}}},{id:"81764",title:"Involvement of the Purinergic System in Cell Death in Models of Retinopathies",doi:"10.5772/intechopen.103935",signatures:"Douglas Penaforte Cruz, Marinna Garcia Repossi and Lucianne Fragel Madeira",slug:"involvement-of-the-purinergic-system-in-cell-death-in-models-of-retinopathies",totalDownloads:4,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Purinergic System",coverURL:"https://cdn.intechopen.com/books/images_new/10801.jpg",subseries:{id:"17",title:"Metabolism"}}},{id:"81756",title:"Alteration of Cytokines Level and Oxidative Stress Parameters in COVID-19",doi:"10.5772/intechopen.104950",signatures:"Marija Petrusevska, Emilija Atanasovska, Dragica Zendelovska, Aleksandar Eftimov and Katerina Spasovska",slug:"alteration-of-cytokines-level-and-oxidative-stress-parameters-in-covid-19",totalDownloads:9,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Chemokines Updates",coverURL:"https://cdn.intechopen.com/books/images_new/11672.jpg",subseries:{id:"18",title:"Proteomics"}}},{id:"81681",title:"Immunomodulatory Effects of a M2-Conditioned Medium (PRS® CK STORM): Theory on the Possible Complex Mechanism of Action through Anti-Inflammatory Modulation of the TLR System and the Purinergic System",doi:"10.5772/intechopen.104486",signatures:"Juan Pedro Lapuente",slug:"immunomodulatory-effects-of-a-m2-conditioned-medium-prs-ck-storm-theory-on-the-possible-complex-mech",totalDownloads:5,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Purinergic System",coverURL:"https://cdn.intechopen.com/books/images_new/10801.jpg",subseries:{id:"17",title:"Metabolism"}}},{id:"81647",title:"Diabetes and Epigenetics",doi:"10.5772/intechopen.104653",signatures:"Rasha A. Alhazzaa, Thomas Heinbockel and Antonei B. Csoka",slug:"diabetes-and-epigenetics",totalDownloads:10,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Epigenetics to Optogenetics - A New Paradigm in the Study of Biology",coverURL:"https://cdn.intechopen.com/books/images_new/9672.jpg",subseries:{id:"14",title:"Cell and Molecular Biology"}}},{id:"81580",title:"Graft-Versus-Host Disease: Pathogenesis and Treatment",doi:"10.5772/intechopen.104450",signatures:"Shin Mukai",slug:"graft-versus-host-disease-pathogenesis-and-treatment",totalDownloads:14,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Purinergic System",coverURL:"https://cdn.intechopen.com/books/images_new/10801.jpg",subseries:{id:"17",title:"Metabolism"}}},{id:"81533",title:"Prenylation of Natural Products: An Overview",doi:"10.5772/intechopen.104636",signatures:"Kantharaju Kamanna and Aravind Kamath",slug:"prenylation-of-natural-products-an-overview",totalDownloads:19,totalCrossrefCites:0,totalDimensionsCites:0,authors:[{name:"Kantharaju",surname:"Kamanna"}],book:{title:"Modifications of Biomolecules",coverURL:"https://cdn.intechopen.com/books/images_new/11098.jpg",subseries:null}},{id:"81067",title:"Encapsulation of Essential Oils and Their Use in Food Applications",doi:"10.5772/intechopen.103147",signatures:"Hamdy A. Shaaban and Amr Farouk",slug:"encapsulation-of-essential-oils-and-their-use-in-food-applications",totalDownloads:47,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Essential Oils - Advances in Extractions and Biological Applications",coverURL:"https://cdn.intechopen.com/books/images_new/11332.jpg",subseries:{id:"15",title:"Chemical Biology"}}},{id:"81099",title:"SK Channels and Heart Disease",doi:"10.5772/intechopen.104115",signatures:"Katherine Zhong, Shawn Kant, Frank Sellke and Jun Feng",slug:"sk-channels-and-heart-disease",totalDownloads:16,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Ion Channels - From Basic Properties to Medical Treatment",coverURL:"https://cdn.intechopen.com/books/images_new/10838.jpg",subseries:{id:"14",title:"Cell and Molecular Biology"}}}]},subseriesFiltersForOFChapters:[{caption:"Proteomics",value:18,count:3,group:"subseries"},{caption:"Metabolism",value:17,count:9,group:"subseries"},{caption:"Cell and Molecular Biology",value:14,count:17,group:"subseries"},{caption:"Chemical Biology",value:15,count:19,group:"subseries"}],publishedBooks:{paginationCount:13,paginationItems:[{type:"book",id:"7102",title:"Pneumonia",subtitle:null,coverURL:"https://cdn.intechopen.com/books/images_new/7102.jpg",slug:"pneumonia",publishedDate:"May 11th 2022",editedByType:"Edited by",bookSignature:"Nima Rezaei",hash:"9fd70142814192dcec58a176749f1b60",volumeInSeries:13,fullTitle:"Pneumonia",editors:[{id:"116250",title:"Dr.",name:"Nima",middleName:null,surname:"Rezaei",slug:"nima-rezaei",fullName:"Nima Rezaei",profilePictureURL:"https://mts.intechopen.com/storage/users/116250/images/system/116250.jpg",institutionString:"Tehran University of Medical Sciences",institution:{name:"Tehran University of Medical Sciences",institutionURL:null,country:{name:"Iran"}}}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null},{type:"book",id:"9615",title:"Chikungunya Virus",subtitle:"A Growing Global Public Health Threat",coverURL:"https://cdn.intechopen.com/books/images_new/9615.jpg",slug:"chikungunya-virus-a-growing-global-public-health-threat",publishedDate:"February 9th 2022",editedByType:"Edited by",bookSignature:"Jean Engohang-Ndong",hash:"c960d94a63867dd12a8ab15176a3ff06",volumeInSeries:12,fullTitle:"Chikungunya Virus - A Growing Global Public Health Threat",editors:[{id:"180733",title:"Dr.",name:"Jean",middleName:null,surname:"Engohang-Ndong",slug:"jean-engohang-ndong",fullName:"Jean Engohang-Ndong",profilePictureURL:"https://mts.intechopen.com/storage/users/180733/images/system/180733.png",institutionString:"Kent State University",institution:{name:"Kent State University",institutionURL:null,country:{name:"United States of America"}}}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null},{type:"book",id:"9619",title:"Epstein-Barr Virus",subtitle:"New Trends",coverURL:"https://cdn.intechopen.com/books/images_new/9619.jpg",slug:"epstein-barr-virus-new-trends",publishedDate:"December 22nd 2021",editedByType:"Edited by",bookSignature:"Emmanuel Drouet",hash:"a2128c53becb6064589570cbe8d976f8",volumeInSeries:11,fullTitle:"Epstein-Barr Virus - New Trends",editors:[{id:"188773",title:"Prof.",name:"Emmanuel",middleName:null,surname:"Drouet",slug:"emmanuel-drouet",fullName:"Emmanuel Drouet",profilePictureURL:"https://mts.intechopen.com/storage/users/188773/images/system/188773.png",institutionString:null,institution:{name:"Grenoble Alpes University",institutionURL:null,country:{name:"France"}}}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null},{type:"book",id:"9525",title:"Insights Into Drug Resistance in Staphylococcus aureus",subtitle:null,coverURL:"https://cdn.intechopen.com/books/images_new/9525.jpg",slug:"insights-into-drug-resistance-in-staphylococcus-aureus",publishedDate:"December 8th 2021",editedByType:"Edited by",bookSignature:"Amjad Aqib",hash:"98bb6c1ddb067da67185c272f81c0a27",volumeInSeries:10,fullTitle:"Insights Into Drug Resistance in Staphylococcus aureus",editors:[{id:"229220",title:"Dr.",name:"Amjad",middleName:"Islam",surname:"Aqib",slug:"amjad-aqib",fullName:"Amjad Aqib",profilePictureURL:"https://mts.intechopen.com/storage/users/229220/images/system/229220.png",institutionString:"Cholistan University of Veterinary and Animal Sciences",institution:null}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null},{type:"book",id:"9614",title:"Advances in Candida albicans",subtitle:null,coverURL:"https://cdn.intechopen.com/books/images_new/9614.jpg",slug:"advances-in-candida-albicans",publishedDate:"November 17th 2021",editedByType:"Edited by",bookSignature:"Xinhui Wang",hash:"31d6882518ca749b12715266eed0a018",volumeInSeries:9,fullTitle:"Advances in Candida albicans",editors:[{id:"296531",title:"Dr.",name:"Xinhui",middleName:null,surname:"Wang",slug:"xinhui-wang",fullName:"Xinhui Wang",profilePictureURL:"https://mts.intechopen.com/storage/users/296531/images/system/296531.jpg",institutionString:"Qinghai Normal University",institution:{name:"University of Luxembourg",institutionURL:null,country:{name:"Luxembourg"}}}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null},{type:"book",id:"9528",title:"Current Topics and Emerging Issues in Malaria Elimination",subtitle:null,coverURL:"https://cdn.intechopen.com/books/images_new/9528.jpg",slug:"current-topics-and-emerging-issues-in-malaria-elimination",publishedDate:"July 21st 2021",editedByType:"Edited by",bookSignature:"Alfonso J. Rodriguez-Morales",hash:"7f178329cc42e691efe226b32f14e2ea",volumeInSeries:8,fullTitle:"Current Topics and Emerging Issues in Malaria Elimination",editors:[{id:"131400",title:"Prof.",name:"Alfonso J.",middleName:null,surname:"Rodriguez-Morales",slug:"alfonso-j.-rodriguez-morales",fullName:"Alfonso J. Rodriguez-Morales",profilePictureURL:"https://mts.intechopen.com/storage/users/131400/images/system/131400.png",institutionString:"Institución Universitaria Visión de las Américas, Colombia",institution:null}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null},{type:"book",id:"9613",title:"Dengue Fever in a One Health Perspective",subtitle:null,coverURL:"https://cdn.intechopen.com/books/images_new/9613.jpg",slug:"dengue-fever-in-a-one-health-perspective",publishedDate:"October 28th 2020",editedByType:"Edited by",bookSignature:"Márcia Aparecida Sperança",hash:"77ecce8195c11092230b4156df6d83ff",volumeInSeries:7,fullTitle:"Dengue Fever in a One Health Perspective",editors:[{id:"176579",title:"Ph.D.",name:"Márcia Aparecida",middleName:null,surname:"Sperança",slug:"marcia-aparecida-speranca",fullName:"Márcia Aparecida Sperança",profilePictureURL:"https://mts.intechopen.com/storage/users/176579/images/system/176579.jpg",institutionString:"Federal University of ABC",institution:{name:"Universidade Federal do ABC",institutionURL:null,country:{name:"Brazil"}}}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null},{type:"book",id:"7981",title:"Overview on Echinococcosis",subtitle:null,coverURL:"https://cdn.intechopen.com/books/images_new/7981.jpg",slug:"overview-on-echinococcosis",publishedDate:"April 22nd 2020",editedByType:"Edited by",bookSignature:"Fethi Derbel and Meriem Braiki",hash:"24dee9209f3fd6b7cd28f042da0076f0",volumeInSeries:6,fullTitle:"Overview on Echinococcosis",editors:[{id:"62900",title:"Prof.",name:"Fethi",middleName:null,surname:"Derbel",slug:"fethi-derbel",fullName:"Fethi Derbel",profilePictureURL:"https://mts.intechopen.com/storage/users/62900/images/system/62900.jpeg",institutionString:"Clinique les Oliviers",institution:null}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null},{type:"book",id:"7887",title:"Hepatitis B and C",subtitle:null,coverURL:"https://cdn.intechopen.com/books/images_new/7887.jpg",slug:"hepatitis-b-and-c",publishedDate:"April 8th 2020",editedByType:"Edited by",bookSignature:"Luis Rodrigo",hash:"8dd6dab483cf505d83caddaeaf497f2c",volumeInSeries:5,fullTitle:"Hepatitis B and C",editors:[{id:"73208",title:"Prof.",name:"Luis",middleName:null,surname:"Rodrigo",slug:"luis-rodrigo",fullName:"Luis Rodrigo",profilePictureURL:"https://mts.intechopen.com/storage/users/73208/images/system/73208.jpg",institutionString:"University of Oviedo",institution:{name:"University of Oviedo",institutionURL:null,country:{name:"Spain"}}}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null},{type:"book",id:"7839",title:"Malaria",subtitle:null,coverURL:"https://cdn.intechopen.com/books/images_new/7839.jpg",slug:"malaria",publishedDate:"December 11th 2019",editedByType:"Edited by",bookSignature:"Fyson H. Kasenga",hash:"91cde4582ead884cb0f355a19b67cd56",volumeInSeries:4,fullTitle:"Malaria",editors:[{id:"86725",title:"Dr.",name:"Fyson",middleName:"Hanania",surname:"Kasenga",slug:"fyson-kasenga",fullName:"Fyson Kasenga",profilePictureURL:"https://mts.intechopen.com/storage/users/86725/images/system/86725.jpg",institutionString:"Malawi Adventist University",institution:{name:"Malawi Adventist University",institutionURL:null,country:{name:"Malawi"}}}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null},{type:"book",id:"7123",title:"Current Topics in Neglected Tropical Diseases",subtitle:null,coverURL:"https://cdn.intechopen.com/books/images_new/7123.jpg",slug:"current-topics-in-neglected-tropical-diseases",publishedDate:"December 4th 2019",editedByType:"Edited by",bookSignature:"Alfonso J. Rodriguez-Morales",hash:"61c627da05b2ace83056d11357bdf361",volumeInSeries:3,fullTitle:"Current Topics in Neglected Tropical Diseases",editors:[{id:"131400",title:"Prof.",name:"Alfonso J.",middleName:null,surname:"Rodriguez-Morales",slug:"alfonso-j.-rodriguez-morales",fullName:"Alfonso J. Rodriguez-Morales",profilePictureURL:"https://mts.intechopen.com/storage/users/131400/images/system/131400.png",institutionString:"Institución Universitaria Visión de las Américas, Colombia",institution:null}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null},{type:"book",id:"7064",title:"Current Perspectives in Human Papillomavirus",subtitle:null,coverURL:"https://cdn.intechopen.com/books/images_new/7064.jpg",slug:"current-perspectives-in-human-papillomavirus",publishedDate:"May 2nd 2019",editedByType:"Edited by",bookSignature:"Shailendra K. Saxena",hash:"d92a4085627bab25ddc7942fbf44cf05",volumeInSeries:2,fullTitle:"Current Perspectives in Human Papillomavirus",editors:[{id:"158026",title:"Prof.",name:"Shailendra K.",middleName:null,surname:"Saxena",slug:"shailendra-k.-saxena",fullName:"Shailendra K. Saxena",profilePictureURL:"https://s3.us-east-1.amazonaws.com/intech-files/0030O00002bRET3QAO/Profile_Picture_2022-05-10T10:10:26.jpeg",institutionString:"King George's Medical University",institution:{name:"King George's Medical University",institutionURL:null,country:{name:"India"}}}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null}]},subseriesFiltersForPublishedBooks:[{group:"subseries",caption:"Bacterial Infectious Diseases",value:3,count:2},{group:"subseries",caption:"Parasitic Infectious Diseases",value:5,count:4},{group:"subseries",caption:"Viral Infectious Diseases",value:6,count:7}],publicationYearFilters:[{group:"publicationYear",caption:"2022",value:2022,count:2},{group:"publicationYear",caption:"2021",value:2021,count:4},{group:"publicationYear",caption:"2020",value:2020,count:3},{group:"publicationYear",caption:"2019",value:2019,count:3},{group:"publicationYear",caption:"2018",value:2018,count:1}],authors:{paginationCount:301,paginationItems:[{id:"116250",title:"Dr.",name:"Nima",middleName:null,surname:"Rezaei",slug:"nima-rezaei",fullName:"Nima Rezaei",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/116250/images/system/116250.jpg",biography:"Professor Nima Rezaei obtained an MD from Tehran University of Medical Sciences, Iran. He also obtained an MSc in Molecular and Genetic Medicine, and a Ph.D. in Clinical Immunology and Human Genetics from the University of Sheffield, UK. He also completed a short-term fellowship in Pediatric Clinical Immunology and Bone Marrow Transplantation at Newcastle General Hospital, England. Dr. Rezaei is a Full Professor of Immunology and Vice Dean of International Affairs and Research, at the School of Medicine, Tehran University of Medical Sciences, and the co-founder and head of the Research Center for Immunodeficiencies. He is also the founding president of the Universal Scientific Education and Research Network (USERN). Dr. Rezaei has directed more than 100 research projects and has designed and participated in several international collaborative projects. He is an editor, editorial assistant, or editorial board member of more than forty international journals. He has edited more than 50 international books, presented more than 500 lectures/posters in congresses/meetings, and published more than 1,100 scientific papers in international journals.",institutionString:"Tehran University of Medical Sciences",institution:{name:"Tehran University of Medical Sciences",country:{name:"Iran"}}},{id:"180733",title:"Dr.",name:"Jean",middleName:null,surname:"Engohang-Ndong",slug:"jean-engohang-ndong",fullName:"Jean Engohang-Ndong",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/180733/images/system/180733.png",biography:"Dr. Jean Engohang-Ndong was born and raised in Gabon. After obtaining his Associate Degree of Science at the University of Science and Technology of Masuku, Gabon, he continued his education in France where he obtained his BS, MS, and Ph.D. in Medical Microbiology. He worked as a post-doctoral fellow at the Public Health Research Institute (PHRI), Newark, NJ for four years before accepting a three-year faculty position at Brigham Young University-Hawaii. Dr. Engohang-Ndong is a tenured faculty member with the academic rank of Full Professor at Kent State University, Ohio, where he teaches a wide range of biological science courses and pursues his research in medical and environmental microbiology. Recently, he expanded his research interest to epidemiology and biostatistics of chronic diseases in Gabon.",institutionString:"Kent State University",institution:{name:"Kent State University",country:{name:"United States of America"}}},{id:"188773",title:"Prof.",name:"Emmanuel",middleName:null,surname:"Drouet",slug:"emmanuel-drouet",fullName:"Emmanuel Drouet",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/188773/images/system/188773.png",biography:"Emmanuel Drouet, PharmD, is a Professor of Virology at the Faculty of Pharmacy, the University Grenoble-Alpes, France. As a head scientist at the Institute of Structural Biology in Grenoble, Dr. Drouet’s research investigates persisting viruses in humans (RNA and DNA viruses) and the balance with our host immune system. He focuses on these viruses’ effects on humans (both their impact on pathology and their symbiotic relationships in humans). He has an excellent track record in the herpesvirus field, and his group is engaged in clinical research in the field of Epstein-Barr virus diseases. He is the editor of the online Encyclopedia of Environment and he coordinates the Universal Health Coverage education program for the BioHealth Computing Schools of the European Institute of Science.",institutionString:null,institution:{name:"Grenoble Alpes University",country:{name:"France"}}},{id:"131400",title:"Prof.",name:"Alfonso J.",middleName:null,surname:"Rodriguez-Morales",slug:"alfonso-j.-rodriguez-morales",fullName:"Alfonso J. Rodriguez-Morales",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/131400/images/system/131400.png",biography:"Dr. Rodriguez-Morales is an expert in tropical and emerging diseases, particularly zoonotic and vector-borne diseases (especially arboviral diseases). He is the president of the Travel Medicine Committee of the Pan-American Infectious Diseases Association (API), as well as the president of the Colombian Association of Infectious Diseases (ACIN). He is a member of the Committee on Tropical Medicine, Zoonoses, and Travel Medicine of ACIN. He is a vice-president of the Latin American Society for Travel Medicine (SLAMVI) and a Member of the Council of the International Society for Infectious Diseases (ISID). Since 2014, he has been recognized as a Senior Researcher, at the Ministry of Science of Colombia. He is a professor at the Faculty of Medicine of the Fundacion Universitaria Autonoma de las Americas, in Pereira, Risaralda, Colombia. He is an External Professor, Master in Research on Tropical Medicine and International Health, Universitat de Barcelona, Spain. He is also a professor at the Master in Clinical Epidemiology and Biostatistics, Universidad Científica del Sur, Lima, Peru. In 2021 he has been awarded the “Raul Isturiz Award” Medal of the API. Also, in 2021, he was awarded with the “Jose Felix Patiño” Asclepius Staff Medal of the Colombian Medical College, due to his scientific contributions to COVID-19 during the pandemic. He is currently the Editor in Chief of the journal Travel Medicine and Infectious Diseases. His Scopus H index is 47 (Google Scholar H index, 68).",institutionString:"Institución Universitaria Visión de las Américas, Colombia",institution:null},{id:"332819",title:"Dr.",name:"Chukwudi Michael",middleName:"Michael",surname:"Egbuche",slug:"chukwudi-michael-egbuche",fullName:"Chukwudi Michael Egbuche",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/332819/images/14624_n.jpg",biography:"I an Dr. Chukwudi Michael Egbuche. I am a Senior Lecturer in the Department of Parasitology and Entomology, Nnamdi Azikiwe University, Awka.",institutionString:null,institution:{name:"Nnamdi Azikiwe University",country:{name:"Nigeria"}}},{id:"284232",title:"Mr.",name:"Nikunj",middleName:"U",surname:"Tandel",slug:"nikunj-tandel",fullName:"Nikunj Tandel",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/284232/images/8275_n.jpg",biography:'Mr. Nikunj Tandel has completed his Master\'s degree in Biotechnology from VIT University, India in the year of 2012. He is having 8 years of research experience especially in the field of malaria epidemiology, immunology, and nanoparticle-based drug delivery system against the infectious diseases, autoimmune disorders and cancer. He has worked for the NIH funded-International Center of Excellence in Malaria Research project "Center for the study of complex malaria in India (CSCMi)" in collaboration with New York University. The preliminary objectives of the study are to understand and develop the evidence-based tools and interventions for the control and prevention of malaria in different sites of the INDIA. Alongside, with the help of next-generation genomics study, the team has studied the antimalarial drug resistance in India. Further, he has extended his research in the development of Humanized mice for the study of liver-stage malaria and identification of molecular marker(s) for the Artemisinin resistance. At present, his research focuses on understanding the role of B cells in the activation of CD8+ T cells in malaria. Received the CSIR-SRF (Senior Research Fellow) award-2018, FIMSA (Federation of Immunological Societies of Asia-Oceania) Travel Bursary award to attend the IUIS-IIS-FIMSA Immunology course-2019',institutionString:"Nirma University",institution:{name:"Nirma University",country:{name:"India"}}},{id:"334383",title:"Ph.D.",name:"Simone",middleName:"Ulrich",surname:"Ulrich Picoli",slug:"simone-ulrich-picoli",fullName:"Simone Ulrich Picoli",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/334383/images/15919_n.jpg",biography:"Graduated in Pharmacy from Universidade Luterana do Brasil (1999), Master in Agricultural and Environmental Microbiology from Federal University of Rio Grande do Sul (2002), Specialization in Clinical Microbiology from Universidade de São Paulo, USP (2007) and PhD in Sciences in Gastroenterology and Hepatology (2012). She is currently an Adjunct Professor at Feevale University in Medicine and Biomedicine courses and a permanent professor of the Academic Master\\'s Degree in Virology. She has experience in the field of Microbiology, with an emphasis on Bacteriology, working mainly on the following topics: bacteriophages, bacterial resistance, clinical microbiology and food microbiology.",institutionString:null,institution:{name:"Universidade Feevale",country:{name:"Brazil"}}},{id:"229220",title:"Dr.",name:"Amjad",middleName:"Islam",surname:"Aqib",slug:"amjad-aqib",fullName:"Amjad Aqib",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/229220/images/system/229220.png",biography:"Dr. Amjad Islam Aqib obtained a DVM and MSc (Hons) from University of Agriculture Faisalabad (UAF), Pakistan, and a PhD from the University of Veterinary and Animal Sciences Lahore, Pakistan. Dr. Aqib joined the Department of Clinical Medicine and Surgery at UAF for one year as an assistant professor where he developed a research laboratory designated for pathogenic bacteria. Since 2018, he has been Assistant Professor/Officer in-charge, Department of Medicine, Manager Research Operations and Development-ORIC, and President One Health Club at Cholistan University of Veterinary and Animal Sciences, Bahawalpur, Pakistan. He has nearly 100 publications to his credit. His research interests include epidemiological patterns and molecular analysis of antimicrobial resistance and modulation and vaccine development against animal pathogens of public health concern.",institutionString:"Cholistan University of Veterinary and Animal Sciences",institution:null},{id:"62900",title:"Prof.",name:"Fethi",middleName:null,surname:"Derbel",slug:"fethi-derbel",fullName:"Fethi Derbel",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/62900/images/system/62900.jpeg",biography:"Professor Fethi Derbel was born in 1960 in Tunisia. He received his medical degree from the Sousse Faculty of Medicine at Sousse, University of Sousse, Tunisia. He completed his surgical residency in General Surgery at the University Hospital Farhat Hached of Sousse and was a member of the Unit of Liver Transplantation in the University of Rennes, France. He then worked in the Department of Surgery at the Sahloul University Hospital in Sousse. Professor Derbel is presently working at the Clinique les Oliviers, Sousse, Tunisia. His hospital activities are mostly concerned with laparoscopic, colorectal, pancreatic, hepatobiliary, and gastric surgery. He is also very interested in hernia surgery and performs ventral hernia repairs and inguinal hernia repairs. He has been a member of the GREPA and Tunisian Hernia Society (THS). During his residency, he managed patients suffering from diabetic foot, and he was very interested in this pathology. For this reason, he decided to coordinate a book project dealing with the diabetic foot. Professor Derbel has published many articles in journals and collaborates intensively with IntechOpen Access Publisher as an editor.",institutionString:"Clinique les Oliviers",institution:null},{id:"300144",title:"Dr.",name:"Meriem",middleName:null,surname:"Braiki",slug:"meriem-braiki",fullName:"Meriem Braiki",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/300144/images/system/300144.jpg",biography:"Dr. Meriem Braiki is a specialist in pediatric surgeon from Tunisia. She was born in 1985. She received her medical degree from the University of Medicine at Sousse, Tunisia. She achieved her surgical residency training periods in Pediatric Surgery departments at University Hospitals in Monastir, Tunis and France.\r\nShe is currently working at the Pediatric surgery department, Sidi Bouzid Hospital, Tunisia. Her hospital activities are mostly concerned with laparoscopic, parietal, urological and digestive surgery. She has published several articles in diffrent journals.",institutionString:"Sidi Bouzid Regional Hospital",institution:null},{id:"229481",title:"Dr.",name:"Erika M.",middleName:"Martins",surname:"de Carvalho",slug:"erika-m.-de-carvalho",fullName:"Erika M. de Carvalho",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/229481/images/6397_n.jpg",biography:null,institutionString:null,institution:{name:"Oswaldo Cruz Foundation",country:{name:"Brazil"}}},{id:"186537",title:"Prof.",name:"Tonay",middleName:null,surname:"Inceboz",slug:"tonay-inceboz",fullName:"Tonay Inceboz",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/186537/images/system/186537.jfif",biography:"I was graduated from Ege University of Medical Faculty (Turkey) in 1988 and completed his Med. PhD degree in Medical Parasitology at the same university. I became an Associate Professor in 2008 and Professor in 2014. I am currently working as a Professor at the Department of Medical Parasitology at Dokuz Eylul University, Izmir, Turkey.\n\nI have given many lectures, presentations in different academic meetings. I have more than 60 articles in peer-reviewed journals, 18 book chapters, 1 book editorship.\n\nMy research interests are Echinococcus granulosus, Echinococcus multilocularis (diagnosis, life cycle, in vitro and in vivo cultivation), and Trichomonas vaginalis (diagnosis, PCR, and in vitro cultivation).",institutionString:"Dokuz Eylül University",institution:{name:"Dokuz Eylül University",country:{name:"Turkey"}}},{id:"71812",title:"Prof.",name:"Hanem Fathy",middleName:"Fathy",surname:"Khater",slug:"hanem-fathy-khater",fullName:"Hanem Fathy Khater",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/71812/images/1167_n.jpg",biography:"Prof. Khater is a Professor of Parasitology at Benha University, Egypt. She studied for her doctoral degree, at the Department of Entomology, College of Agriculture, Food and Natural Resources, University of Missouri, Columbia, USA. She has completed her Ph.D. degrees in Parasitology in Egypt, from where she got the award for “the best scientific Ph.D. dissertation”. She worked at the School of Biological Sciences, Bristol, England, the UK in controlling insects of medical and veterinary importance as a grant from Newton Mosharafa, the British Council. Her research is focused on searching of pesticides against mosquitoes, house flies, lice, green bottle fly, camel nasal botfly, soft and hard ticks, mites, and the diamondback moth as well as control of several parasites using safe and natural materials to avoid drug resistances and environmental contamination.",institutionString:null,institution:{name:"Banha University",country:{name:"Egypt"}}},{id:"99780",title:"Prof.",name:"Omolade",middleName:"Olayinka",surname:"Okwa",slug:"omolade-okwa",fullName:"Omolade Okwa",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/99780/images/system/99780.jpg",biography:"Omolade Olayinka Okwa is presently a Professor of Parasitology at Lagos State University, Nigeria. She has a PhD in Parasitology (1997), an MSc in Cellular Parasitology (1992), and a BSc (Hons) Zoology (1990) all from the University of Ibadan, Nigeria. She teaches parasitology at the undergraduate and postgraduate levels. She was a recipient of a Commonwealth fellowship supported by British Council tenable at the Centre for Entomology and Parasitology (CAEP), Keele University, United Kingdom between 2004 and 2005. She was awarded an Honorary Visiting Research Fellow at the same university from 2005 to 2007. \nShe has been an external examiner to the Department of Veterinary Microbiology and Parasitology, University of Ibadan, MSc programme between 2010 and 2012. She is a member of the Nigerian Society of Experimental Biology (NISEB), Parasitology and Public Health Society of Nigeria (PPSN), Science Association of Nigeria (SAN), Zoological Society of Nigeria (ZSN), and is Vice Chairperson of the Organisation of Women in Science (OWSG), LASU chapter. She served as Head of Department of Zoology and Environmental Biology, Lagos State University from 2007 to 2010 and 2014 to 2016. She is a reviewer for several local and international journals such as Unilag Journal of Science, Libyan Journal of Medicine, Journal of Medicine and Medical Sciences, and Annual Research and Review in Science. \nShe has authored 45 scientific research publications in local and international journals, 8 scientific reviews, 4 books, and 3 book chapters, which includes the books “Malaria Parasites” and “Malaria” which are IntechOpen access publications.",institutionString:"Lagos State University",institution:{name:"Lagos State University",country:{name:"Nigeria"}}},{id:"273100",title:"Dr.",name:"Vijay",middleName:null,surname:"Gayam",slug:"vijay-gayam",fullName:"Vijay Gayam",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/273100/images/system/273100.jpeg",biography:"Dr. Vijay Bhaskar Reddy Gayam is currently practicing as an internist at Interfaith Medical Center in Brooklyn, New York, USA. He is also a Clinical Assistant Professor at the SUNY Downstate University Hospital and Adjunct Professor of Medicine at the American University of Antigua. He is a holder of an M.B.B.S. degree bestowed to him by Osmania Medical College and received his M.D. at Interfaith Medical Center. His career goals thus far have heavily focused on direct patient care, medical education, and clinical research. He currently serves in two leadership capacities; Assistant Program Director of Medicine at Interfaith Medical Center and as a Councilor for the American\r\nFederation for Medical Research. As a true academician and researcher, he has more than 50 papers indexed in international peer-reviewed journals. He has also presented numerous papers in multiple national and international scientific conferences. His areas of research interest include general internal medicine, gastroenterology and hepatology. He serves as an editor, editorial board member and reviewer for multiple international journals. His research on Hepatitis C has been very successful and has led to multiple research awards, including the 'Equity in Prevention and Treatment Award” from the New York Department of Health Viral Hepatitis Symposium (2018) and the 'Presidential Poster Award” awarded to him by the American College of Gastroenterology (2018). He was also awarded 'Outstanding Clinician in General Medicine” by Venus International Foundation for his extensive research expertise and services, perform over and above the standard expected in the advancement of healthcare, patient safety and quality of care.",institutionString:"Interfaith Medical Center",institution:{name:"Interfaith Medical Center",country:{name:"United States of America"}}},{id:"93517",title:"Dr.",name:"Clement",middleName:"Adebajo",surname:"Meseko",slug:"clement-meseko",fullName:"Clement Meseko",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/93517/images/system/93517.jpg",biography:"Dr. Clement Meseko obtained DVM and PhD degree in Veterinary Medicine and Virology respectively. He has worked for over 20 years in both private and public sectors including the academia, contributing to knowledge and control of infectious disease. Through the application of epidemiological skill, classical and molecular virological skills, he investigates viruses of economic and public health importance for the mitigation of the negative impact on people, animal and the environment in the context of Onehealth. \r\nDr. Meseko’s field experience on animal and zoonotic diseases and pathogen dynamics at the human-animal interface over the years shaped his carrier in research and scientific inquiries. He has been part of the investigation of Highly Pathogenic Avian Influenza incursions in sub Saharan Africa and monitors swine Influenza (Pandemic influenza Virus) agro-ecology and potential for interspecies transmission. He has authored and reviewed a number of journal articles and book chapters.",institutionString:"National Veterinary Research Institute",institution:{name:"National Veterinary Research Institute",country:{name:"Nigeria"}}},{id:"158026",title:"Prof.",name:"Shailendra K.",middleName:null,surname:"Saxena",slug:"shailendra-k.-saxena",fullName:"Shailendra K. Saxena",position:null,profilePictureURL:"https://s3.us-east-1.amazonaws.com/intech-files/0030O00002bRET3QAO/Profile_Picture_2022-05-10T10:10:26.jpeg",biography:"Professor Dr. Shailendra K. Saxena is a vice dean and professor at King George's Medical University, Lucknow, India. His research interests involve understanding the molecular mechanisms of host defense during human viral infections and developing new predictive, preventive, and therapeutic strategies for them using Japanese encephalitis virus (JEV), HIV, and emerging viruses as a model via stem cell and cell culture technologies. His research work has been published in various high-impact factor journals (Science, PNAS, Nature Medicine) with a high number of citations. He has received many awards and honors in India and abroad including various Young Scientist Awards, BBSRC India Partnering Award, and Dr. JC Bose National Award of Department of Biotechnology, Min. of Science and Technology, Govt. of India. Dr. Saxena is a fellow of various international societies/academies including the Royal College of Pathologists, United Kingdom; Royal Society of Medicine, London; Royal Society of Biology, United Kingdom; Royal Society of Chemistry, London; and Academy of Translational Medicine Professionals, Austria. He was named a Global Leader in Science by The Scientist. He is also an international opinion leader/expert in vaccination for Japanese encephalitis by IPIC (UK).",institutionString:"King George's Medical University",institution:{name:"King George's Medical University",country:{name:"India"}}},{id:"94928",title:"Dr.",name:"Takuo",middleName:null,surname:"Mizukami",slug:"takuo-mizukami",fullName:"Takuo Mizukami",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/94928/images/6402_n.jpg",biography:null,institutionString:null,institution:{name:"National Institute of Infectious Diseases",country:{name:"Japan"}}},{id:"233433",title:"Dr.",name:"Yulia",middleName:null,surname:"Desheva",slug:"yulia-desheva",fullName:"Yulia Desheva",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/233433/images/system/233433.png",biography:"Dr. Yulia Desheva is a leading researcher at the Institute of Experimental Medicine, St. Petersburg, Russia. She is a professor in the Stomatology Faculty, St. Petersburg State University. She has expertise in the development and evaluation of a wide range of live mucosal vaccines against influenza and bacterial complications. Her research interests include immunity against influenza and COVID-19 and the development of immunization schemes for high-risk individuals.",institutionString:'Federal State Budgetary Scientific Institution "Institute of Experimental Medicine"',institution:null},{id:"238958",title:"Mr.",name:"Atamjit",middleName:null,surname:"Singh",slug:"atamjit-singh",fullName:"Atamjit Singh",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/238958/images/6575_n.jpg",biography:null,institutionString:null,institution:null},{id:"333753",title:"Dr.",name:"Rais",middleName:null,surname:"Ahmed",slug:"rais-ahmed",fullName:"Rais Ahmed",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/333753/images/20168_n.jpg",biography:null,institutionString:null,institution:null},{id:"252058",title:"M.Sc.",name:"Juan",middleName:null,surname:"Sulca",slug:"juan-sulca",fullName:"Juan Sulca",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/252058/images/12834_n.jpg",biography:null,institutionString:null,institution:null},{id:"191392",title:"Dr.",name:"Marimuthu",middleName:null,surname:"Govindarajan",slug:"marimuthu-govindarajan",fullName:"Marimuthu Govindarajan",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/191392/images/5828_n.jpg",biography:"Dr. M. Govindarajan completed his BSc degree in Zoology at Government Arts College (Autonomous), Kumbakonam, and MSc, MPhil, and PhD degrees at Annamalai University, Annamalai Nagar, Tamil Nadu, India. He is serving as an assistant professor at the Department of Zoology, Annamalai University. His research interests include isolation, identification, and characterization of biologically active molecules from plants and microbes. He has identified more than 20 pure compounds with high mosquitocidal activity and also conducted high-quality research on photochemistry and nanosynthesis. He has published more than 150 studies in journals with impact factor and 2 books in Lambert Academic Publishing, Germany. He serves as an editorial board member in various national and international scientific journals.",institutionString:null,institution:null},{id:"274660",title:"Dr.",name:"Damodar",middleName:null,surname:"Paudel",slug:"damodar-paudel",fullName:"Damodar Paudel",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/274660/images/8176_n.jpg",biography:"I am DrDamodar Paudel,currently working as consultant Physician in Nepal police Hospital.",institutionString:null,institution:null},{id:"241562",title:"Dr.",name:"Melvin",middleName:null,surname:"Sanicas",slug:"melvin-sanicas",fullName:"Melvin Sanicas",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/241562/images/6699_n.jpg",biography:null,institutionString:null,institution:null},{id:"337446",title:"Dr.",name:"Maria",middleName:null,surname:"Zavala-Colon",slug:"maria-zavala-colon",fullName:"Maria Zavala-Colon",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"University of Puerto Rico, Medical Sciences Campus",country:{name:"United States of America"}}},{id:"338856",title:"Mrs.",name:"Nur Alvira",middleName:null,surname:"Pascawati",slug:"nur-alvira-pascawati",fullName:"Nur Alvira Pascawati",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"Universitas Respati Yogyakarta",country:{name:"Indonesia"}}},{id:"441116",title:"Dr.",name:"Jovanka M.",middleName:null,surname:"Voyich",slug:"jovanka-m.-voyich",fullName:"Jovanka M. Voyich",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"Montana State University",country:{name:"United States of America"}}},{id:"330412",title:"Dr.",name:"Muhammad",middleName:null,surname:"Farhab",slug:"muhammad-farhab",fullName:"Muhammad Farhab",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"University of Agriculture Faisalabad",country:{name:"Pakistan"}}},{id:"349495",title:"Dr.",name:"Muhammad",middleName:null,surname:"Ijaz",slug:"muhammad-ijaz",fullName:"Muhammad Ijaz",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"University of Veterinary and Animal Sciences",country:{name:"Pakistan"}}}]}},subseries:{item:{id:"20",type:"subseries",title:"Animal Nutrition",keywords:"Sustainable Animal Diets, Carbon Footprint, Meta Analyses",scope:"An essential part of animal production is nutrition. Animals need to receive a properly balanced diet. One of the new challenges we are now faced with is sustainable animal diets (STAND) that involve the 3 P’s (People, Planet, and Profitability). We must develop animal feed that does not compete with human food, use antibiotics, and explore new growth promoters options, such as plant extracts or compounds that promote feed efficiency (e.g., monensin, oils, enzymes, probiotics). These new feed options must also be environmentally friendly, reducing the Carbon footprint, CH4, N, and P emissions to the environment, with an adequate formulation of nutrients.",coverUrl:"https://cdn.intechopen.com/series_topics/covers/20.jpg",hasOnlineFirst:!0,hasPublishedBooks:!0,annualVolume:11416,editor:{id:"175967",title:"Dr.",name:"Manuel",middleName:null,surname:"Gonzalez Ronquillo",slug:"manuel-gonzalez-ronquillo",fullName:"Manuel Gonzalez Ronquillo",profilePictureURL:"https://mts.intechopen.com/storage/users/175967/images/system/175967.png",biography:"Dr. Manuel González Ronquillo obtained his doctorate degree from the University of Zaragoza, Spain, in 2001. He is a research professor at the Faculty of Veterinary Medicine and Animal Husbandry, Autonomous University of the State of Mexico. He is also a level-2 researcher. He received a Fulbright-Garcia Robles fellowship for a postdoctoral stay at the US Dairy Forage Research Center, Madison, Wisconsin, USA in 2008–2009. He received grants from Alianza del Pacifico for a stay at the University of Magallanes, Chile, in 2014, and from Consejo Nacional de Ciencia y Tecnología (CONACyT) to work in the Food and Agriculture Organization’s Animal Production and Health Division (AGA), Rome, Italy, in 2014–2015. He has collaborated with researchers from different countries and published ninety-eight journal articles. He teaches various degree courses in zootechnics, sheep production, and agricultural sciences and natural resources.\n\nDr. Ronquillo’s research focuses on the evaluation of sustainable animal diets (StAnD), using native resources of the region, decreasing carbon footprint, and applying meta-analysis and mathematical models for a better understanding of animal production.",institutionString:null,institution:{name:"Universidad Autónoma del Estado de México",institutionURL:null,country:{name:"Mexico"}}},editorTwo:null,editorThree:null,series:{id:"13",title:"Veterinary Medicine and Science",doi:"10.5772/intechopen.73681",issn:"2632-0517"},editorialBoard:[{id:"175762",title:"Dr.",name:"Alfredo J.",middleName:null,surname:"Escribano",slug:"alfredo-j.-escribano",fullName:"Alfredo J. Escribano",profilePictureURL:"https://s3.us-east-1.amazonaws.com/intech-files/0030O00002bRGnzQAG/Profile_Picture_1633076636544",institutionString:"Consultant and Independent Researcher in Industry Sector, Spain",institution:null},{id:"310962",title:"Dr.",name:"Amlan",middleName:"Kumar",surname:"Patra",slug:"amlan-patra",fullName:"Amlan Patra",profilePictureURL:"https://mts.intechopen.com/storage/users/310962/images/system/310962.jpg",institutionString:null,institution:{name:"West Bengal University of Animal and Fishery Sciences",institutionURL:null,country:{name:"India"}}},{id:"216995",title:"Prof.",name:"Figen",middleName:null,surname:"Kırkpınar",slug:"figen-kirkpinar",fullName:"Figen Kırkpınar",profilePictureURL:"https://s3.us-east-1.amazonaws.com/intech-files/0030O00002bRMzxQAG/Profile_Picture_1625722918145",institutionString:null,institution:{name:"Ege University",institutionURL:null,country:{name:"Turkey"}}}]},onlineFirstChapters:{paginationCount:9,paginationItems:[{id:"80495",title:"Iron in Cell Metabolism and Disease",doi:"10.5772/intechopen.101908",signatures:"Eeka Prabhakar",slug:"iron-in-cell-metabolism-and-disease",totalDownloads:2,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Iron Metabolism - Iron a Double‐Edged Sword",coverURL:"https://cdn.intechopen.com/books/images_new/10842.jpg",subseries:{id:"17",title:"Metabolism"}}},{id:"81799",title:"Cross Talk of Purinergic and Immune Signaling: Implication in Inflammatory and Pathogenic Diseases",doi:"10.5772/intechopen.104978",signatures:"Richa Rai",slug:"cross-talk-of-purinergic-and-immune-signaling-implication-in-inflammatory-and-pathogenic-diseases",totalDownloads:7,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Purinergic System",coverURL:"https://cdn.intechopen.com/books/images_new/10801.jpg",subseries:{id:"17",title:"Metabolism"}}},{id:"81764",title:"Involvement of the Purinergic System in Cell Death in Models of Retinopathies",doi:"10.5772/intechopen.103935",signatures:"Douglas Penaforte Cruz, Marinna Garcia Repossi and Lucianne Fragel Madeira",slug:"involvement-of-the-purinergic-system-in-cell-death-in-models-of-retinopathies",totalDownloads:4,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Purinergic System",coverURL:"https://cdn.intechopen.com/books/images_new/10801.jpg",subseries:{id:"17",title:"Metabolism"}}},{id:"81681",title:"Immunomodulatory Effects of a M2-Conditioned Medium (PRS® CK STORM): Theory on the Possible Complex Mechanism of Action through Anti-Inflammatory Modulation of the TLR System and the Purinergic System",doi:"10.5772/intechopen.104486",signatures:"Juan Pedro Lapuente",slug:"immunomodulatory-effects-of-a-m2-conditioned-medium-prs-ck-storm-theory-on-the-possible-complex-mech",totalDownloads:5,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Purinergic System",coverURL:"https://cdn.intechopen.com/books/images_new/10801.jpg",subseries:{id:"17",title:"Metabolism"}}},{id:"81580",title:"Graft-Versus-Host Disease: Pathogenesis and Treatment",doi:"10.5772/intechopen.104450",signatures:"Shin Mukai",slug:"graft-versus-host-disease-pathogenesis-and-treatment",totalDownloads:14,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Purinergic System",coverURL:"https://cdn.intechopen.com/books/images_new/10801.jpg",subseries:{id:"17",title:"Metabolism"}}},{id:"80485",title:"Potential Marker for Diagnosis and Screening of Iron Deficiency Anemia in Children",doi:"10.5772/intechopen.102792",signatures:"Yulia Nadar Indrasari, Siti Nurul Hapsari and Muhamad Robiul Fuadi",slug:"potential-marker-for-diagnosis-and-screening-of-iron-deficiency-anemia-in-children",totalDownloads:42,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Iron Metabolism - Iron a Double‐Edged Sword",coverURL:"https://cdn.intechopen.com/books/images_new/10842.jpg",subseries:{id:"17",title:"Metabolism"}}},{id:"79693",title:"Ferroptosis: Can Iron be the Last or Cure for a Cell?",doi:"10.5772/intechopen.101426",signatures:"Asuman Akkaya Fırat",slug:"ferroptosis-can-iron-be-the-last-or-cure-for-a-cell",totalDownloads:90,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Iron Metabolism - Iron a Double‐Edged Sword",coverURL:"https://cdn.intechopen.com/books/images_new/10842.jpg",subseries:{id:"17",title:"Metabolism"}}},{id:"79616",title:"Dietary Iron",doi:"10.5772/intechopen.101265",signatures:"Kouser Firdose and Noor Firdose",slug:"dietary-iron",totalDownloads:142,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Iron Metabolism - Iron a Double‐Edged Sword",coverURL:"https://cdn.intechopen.com/books/images_new/10842.jpg",subseries:{id:"17",title:"Metabolism"}}},{id:"78977",title:"FERALGINE™ a New Oral iron Compound",doi:"10.5772/intechopen.100445",signatures:"Valentina Talarico, Laura Giancotti, Giuseppe Antonio Mazza, Santina Marrazzo, Roberto Miniero and Marco Bertini",slug:"feralgine-a-new-oral-iron-compound",totalDownloads:129,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Iron Metabolism - Iron a Double‐Edged Sword",coverURL:"https://cdn.intechopen.com/books/images_new/10842.jpg",subseries:{id:"17",title:"Metabolism"}}}]},publishedBooks:{paginationCount:2,paginationItems:[{type:"book",id:"10830",title:"Animal Feed Science and Nutrition",subtitle:"Production, Health and Environment",coverURL:"https://cdn.intechopen.com/books/images_new/10830.jpg",slug:"animal-feed-science-and-nutrition-production-health-and-environment",publishedDate:"May 18th 2022",editedByType:"Edited by",bookSignature:"Amlan Kumar Patra",hash:"79944fc8fbbaa329aed6fde388154832",volumeInSeries:10,fullTitle:"Animal Feed Science and Nutrition - Production, Health and Environment",editors:[{id:"310962",title:"Dr.",name:"Amlan",middleName:"Kumar",surname:"Patra",slug:"amlan-patra",fullName:"Amlan Patra",profilePictureURL:"https://mts.intechopen.com/storage/users/310962/images/system/310962.jpg",institutionString:null,institution:{name:"West Bengal University of Animal and Fishery Sciences",institutionURL:null,country:{name:"India"}}}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null},{type:"book",id:"10496",title:"Advanced Studies in the 21st Century Animal Nutrition",subtitle:null,coverURL:"https://cdn.intechopen.com/books/images_new/10496.jpg",slug:"advanced-studies-in-the-21st-century-animal-nutrition",publishedDate:"December 8th 2021",editedByType:"Edited by",bookSignature:"László Babinszky, Juliana Oliveira and Edson Mauro Santos",hash:"8ffe43a82ac48b309abc3632bbf3efd0",volumeInSeries:8,fullTitle:"Advanced Studies in the 21st Century Animal Nutrition",editors:[{id:"53998",title:"Prof.",name:"László",middleName:null,surname:"Babinszky",slug:"laszlo-babinszky",fullName:"László Babinszky",profilePictureURL:"https://mts.intechopen.com/storage/users/53998/images/system/53998.png",institutionString:"University of Debrecen",institution:{name:"University of Debrecen",institutionURL:null,country:{name:"Hungary"}}}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null}]},testimonialsList:[{id:"18",text:"It was great publishing with IntechOpen, the process was straightforward and I had support all along.",author:{id:"71579",name:"Berend",surname:"Olivier",institutionString:"Utrecht University",profilePictureURL:"https://mts.intechopen.com/storage/users/71579/images/system/71579.jpg",slug:"berend-olivier",institution:{id:"253",name:"Utrecht University",country:{id:null,name:"Netherlands"}}}},{id:"27",text:"The opportunity to work with a prestigious publisher allows for the possibility to collaborate with more research groups interested in animal nutrition, leading to the development of new feeding strategies and food valuation while being more sustainable with the environment, allowing more readers to learn about the subject.",author:{id:"175967",name:"Manuel",surname:"Gonzalez Ronquillo",institutionString:null,profilePictureURL:"https://mts.intechopen.com/storage/users/175967/images/system/175967.png",slug:"manuel-gonzalez-ronquillo",institution:{id:"6221",name:"Universidad Autónoma del Estado de México",country:{id:null,name:"Mexico"}}}},{id:"8",text:"I work with IntechOpen for a number of reasons: their professionalism, their mission in support of Open Access publishing, and the quality of their peer-reviewed publications, but also because they believe in equality.",author:{id:"202192",name:"Catrin",surname:"Rutland",institutionString:null,profilePictureURL:"https://mts.intechopen.com/storage/users/202192/images/system/202192.png",slug:"catrin-rutland",institution:{id:"134",name:"University of Nottingham",country:{id:null,name:"United Kingdom"}}}}]},submityourwork:{pteSeriesList:[],lsSeriesList:[],hsSeriesList:[],sshSeriesList:[],subseriesList:[],annualVolumeBook:{},thematicCollection:[],selectedSeries:null,selectedSubseries:null},seriesLanding:{item:null},libraryRecommendation:{success:null,errors:{},institutions:[]},route:{name:"profile.detail",path:"/profiles/55212",hash:"",query:{},params:{id:"55212"},fullPath:"/profiles/55212",meta:{},from:{name:null,path:"/",hash:"",query:{},params:{},fullPath:"/",meta:{}}}},function(){var e;(e=document.currentScript||document.scripts[document.scripts.length-1]).parentNode.removeChild(e)}()